Method for producing L-erythrobiopterin compounds

The use of boric acid esters and chiral amino alcohols for chiral resolution in the production of L-erythro-biopterin compounds addresses inefficiencies and environmental concerns, resulting in high-purity and cost-effective industrial production.

JP7587862B2Active Publication Date: 2024-11-21SHANGHAI FOREFRONT PHARMCEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2022511260
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-08-12
Filing Date
2020-08-18
Publication Date
2024-11-21
Estimated Expiration
2040-08-18

AI Technical Summary

Technical Problem

Current methods for producing L-erythro-biopterin compounds are inefficient, costly, environmentally unfriendly, and unsuitable for industrial production due to issues such as unstable intermediates, low yield, and poor solubility, leading to high production costs and low quality sapropterin hydrochloride.

Method used

A method involving the use of boric acid esters and chiral amino alcohols for chiral resolution, followed by a dihydroxylation reaction to produce L-erythro-biopterin compounds, which avoids unstable intermediates and improves yield and solubility, making it suitable for industrial production.

Benefits of technology

The method achieves high purity and efficiency in producing L-erythro-biopterin compounds, reducing production costs and environmental impact, and is suitable for large-scale manufacturing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007587862000174
    Figure 0007587862000174
  • Figure 0007587862000001
    Figure 0007587862000001
  • Figure 0007587862000002
    Figure 0007587862000002
Patent Text Reader

Abstract

The present invention relates to a method for producing an L-erythrobiopterin-like compound, wherein the L-erythrobiopterin-like compound has a structure represented by formula (I), and the L-erythrobiopterin-like compound represented by formula (I) is mainly produced by dihydroxylation reaction from a compound represented by formula (II) or formula (III); [Formula 1] TIFF2022545102000176.tif55155This method for producing L-erythrobiopterin compounds has high production efficiency, low cost, and is environmentally friendly, making it suitable for industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] This application seeks to incorporate by reference the priority claims of the following Chinese patent applications: Application No. 2019107645414, entitled "Method for producing L-erythrobiopterin compounds," filed on August 19, 2019 to the China Patent Office, and Application No. 2020108063470, entitled "Intermediate for producing L-erythro-biopterin compounds and method for producing same," filed on August 12, 2020 to the China Patent Office.

[0002] (Technical field) The present invention relates to the technical field of pharmaceutical production, and in particular to a method for producing L-erythro-biopterin compounds. [Background technology]

[0003] L-erythro-biopterin compounds represented by formula (I) have been important intermediates for many pharmaceuticals, especially sapropterin preparations. For example, (R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydropteridin-4(3H)-one (BH4) represented by formula (Ib) is a coenzyme required for hydroxylation and oxygenase in vivo, and acts as the most important coenzyme for nitric oxide synthase (NOS). Its hydrochloride (i.e., sapropterin dihydrochloride, structural formula: formula (Ic)) has been approved by many countries as a therapeutic agent for phenylketonuria.

[0004] [ka]

[0005] However, the main method for synthesizing sapropterin dihydrochloride in the past is to obtain it by hydrogenation reduction using the compound represented by formula (Ia).

[0006] [ka]

[0007] Therefore, the focus of research and development has been on how to obtain the L-erythro-biopterin compound represented by formula (Ia) safely and effectively.

[0008] At present, there are many reports on the synthesis of L-erythro-biopterin compounds. For example, Andrews et al. (J. Chem. Soc. 1969, 928) reported the synthesis of biopterin by condensing 5-deoxy-L-arabinose with 2-amino-4-chloro-3-nitro-6-hydroxypyrimidine, but the optical purity and chemical purity of the synthesis are insufficient and cannot be scaled up.

[0009] Welustock J. (US3505329) and Taylor EC (J.Am. Chem. Soc. 1979, 98, 2301) have reported a method with higher optical selectivity, the route of which is shown below.

[0010] [ka]

[0011] Starting from L-rhamnose, it is reacted with ethanethiol to produce a mercaptal, which is then oxidized to a sulfone, followed by the removal of one carbon by alkali treatment to give 5-deoxy-L-arabinose (D). 5-deoxy-L-arabinose is then reacted with 2,4,5-triamino-6-hydroxypyrimidine (TAP) to produce L-erythro-biopterin. Subsequent improvements (Helv chim acta 1985:1639) have led to the current industrial route. The method is to first treat 5-deoxy-L-arabinose (D) with phenylhydrazine, then with acetic anhydride to convert it to the corresponding acetyl benzylhydrazone (G). It is then cyclized with TAP, which is immediately oxidized without separation to give acetylated L-erythro-biopterin. It is then deprotected to give L-erythro-biopterin.

[0012] However, this industrialization route has major drawbacks. 1) In the synthesis of the key intermediate 5-deoxy-L-arabinose, it is necessary to produce an acetal by condensing L-rhamnose with ethanethiol, which has a foul odor, which is complicated and polluting, and is not currently used industrially; 2) The intermediate 5-deoxy-L-arabinose itself is unstable and cannot be stored for a long time, so it must be prepared just before use; 3) The intermediates in all steps of the production of 5-deoxy-L-arabinose are oily and unstable, so it is difficult to convert C- to L-erythro-biphenylylamine using crude products. 4) The production of L-erythro-biopterin by condensation of 5-deoxy-L-arabinose derivatives with 2,4,5-triamino-6-hydroxypyrimidine (TAP) has low selectivity, high impurity content, and low yield; 5) The produced L-erythro-biopterin has very poor solubility in common solvents, making purification very difficult and of poor quality, which adversely affects the quality of sapropterin hydrochloride produced by subsequent hydrogenation.

[0013] In view of the prior art, the process improvements of L-erythro-biopterin compounds in the world are still mostly limited to the production of 5-deoxy-L-arabinose, and other reagents are used instead of mercaptan, especially to reduce odor and pollution. There has been no significant progress in the condensation of 5-deoxy-L-arabinose derivatives with TAP, and the raw materials are expensive, the pathway is long, and the yield is low, resulting in high production costs and low safety, which cannot meet the needs of modern pharmaceutical manufacturing. Therefore, there is an urgent need to develop a low-cost, efficient, environmentally friendly method for producing L-erythro-biopterin compounds that is suitable for industrialized production. Detailed Description of the Invention

[0014] In view of the above, the present invention provides a method for producing L-erythro-biopterin compounds, which has high production efficiency, low cost, is environmentally friendly, and is suitable for industrial production.

[0015] An intermediate having a structure represented by formula (IVa-1), formula (IVa-2), formula (IVa-3), formula (IVa-4), formula (IVa) or formula (IVa'), [ka] During the ceremony, [ka] represents the structure produced by reacting dihydroxy with the first and second reagents; [ka] represents the structure formed by reacting dihydroxy with the first reagent; The first reagent is a borate ester or boric acid; the second reagent is a chiral amino alcohol; W is NH x where X is 0, 1 or 2; R 1 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocycloalkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group; R 2 and R 3 are each independently a hydrogen atom or a protecting group for an amino group, R 2 and R 3 is the above R 2 and R 3 can form a cyclic lactam group with the nitrogen atom bonded to R 4 -COOR 5 , -CONR 6 or -CN; R 5 and R 6each independently represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocycloalkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group; Z is a hydrogen atom or a leaving group; Y is O or absent.

[0016] A method for producing said intermediate, comprising the steps of:

[0017] The compound to be resolved, the first reagent, the second reagent, and an aprotic solvent are mixed and heated under reflux. After the reaction is completed, the mixture is crystallized to obtain an intermediate having a structure represented by formula (IVa-1) or formula (IVa-2); the compound to be resolved is a mixture of formula (IVa) and formula (IVa'); [ka]

[0018] The application of said intermediate in the preparation of L-erythro-biopterin compounds.

[0019] A method for producing an L-erythro-biopterin compound, the L-erythro-biopterin compound having a structure represented by formula (I), the L-erythro-biopterin compound represented by formula (I) being produced by a dihydroxylation reaction from a compound represented by formula (II) or a compound represented by formula (III); [ka]

[0020] During the ceremony, Y is O or absent; Z is a hydrogen atom or a leaving group; R 1is a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocycloalkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group; R 2 and R 3 are each independently a hydrogen atom or a protecting group for an amino group, 2 and R 3 is the above R 2 and R 3 can form a cyclic imido group with the nitrogen atom bonded to R 4 -COOR 5 , -CONH 6 or -CN; R 5 and R 6 each independently represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocycloalkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group; R7 is -OH or -NH2.

[0021] An L-erythro-biopterin compound produced by the method for producing an L-erythro-biopterin compound.

[0022] A method for producing a sapropterin formulation, comprising the steps of: The L-erythro-biopterin compound represented by formula (I) is produced by the method for producing the L-erythro-biopterin compound; The L-erythro-biopterin compound represented by formula (I) is reduced by hydrogenation. The application of said L-erythro-biopterin class compound in the manufacture of medicines for treating phenylketonuria and hyperphenylalaninemia.

[0023] The application of said method for producing L-erythro-biopterin compounds in the production of medicines for treating phenylketonuria and hyperphenylalaninemia. [Brief description of the drawings]

[0024] [Figure 1] FIG. 1 is a single crystal diagram of compound 3a. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0025] In order to facilitate understanding of the present invention, the present invention will be described in more detail below, and more preferred embodiments of the present invention will be shown. However, the present invention can be embodied in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided to provide a more thorough and complete understanding of the present disclosure.

[0026] All technical and scientific terms used herein have the same meaning as commonly understood by a person skilled in the art of the present invention unless otherwise defined. Terms used in the present specification are used only to describe specific embodiments and are not intended to limit the present invention. The term "and / or" used herein includes any one or more of the associated items and combinations thereof.

[0027] Terms / Definitions In the present invention, unless otherwise specified, the same symbols should be understood to have the same meaning. In addition, unless otherwise specified, each term in the present invention (including abbreviations of substituents, reagent names, etc.) should be understood to have the usual meaning in the relevant field.

[0028] In the present invention, group means an atom or functional group that can be removed from a larger molecule in a chemical reaction, and should be understood as having the usual meaning in the art.Unless otherwise specified, the process in which a leaving group-containing compound participates in a reaction includes the introduction process and removal process of a leaving group, and the introduction and removal of the leaving group can use a method generally used in the art according to the specific type of the leaving group used, and is not particularly limited here.

[0029] In the present invention, the amino-protecting group means a protecting group of an amino group, and should be understood as having the usual meaning in the art. Unless otherwise specified, the process in which a protecting group-containing compound participates in a reaction includes a process of introducing and removing a protecting group, and the introduction and removal of a protecting group can be performed by a method generally used in the art according to the type of protecting group used, and is not particularly limited here.

[0030] In the present invention, "substituted or unsubstituted" means that the defined group is substituted or unsubstituted. When the defined group is substituted, it should be understood that the substituted group is arbitrarily selected from groups acceptable in the art. Acceptable groups include an alkyl group having 1 to 20 C atoms, a cycloalkyl group having 3 to 20 ring atoms, a heterocyclyl group having 3 to 20 ring atoms, an aryl group having 5 to 20 ring atoms, a cyclic ... The above-mentioned groups include, but are not limited to, a heteroaryl group, a silyl group, a carbonyl group, an alkoxycarbonyl group, an aryloxycarbonyl group, a carbamoyl group, a halogenated formyl group, a formyl group, -NRR', a cyano group, an isocyanate group, a thiocyanate group, an isothiocyanate group, a hydroxy group, a trifluoromethyl group, a nitro group, or a halogen group, and the above-mentioned groups may be further substituted with a substituent acceptable in the art; R and R' in -NRR' are each independently substituted with a group acceptable in the art, and the acceptable groups include H, an alkyl group having 1 to 6 C atoms, a cycloalkyl group having 3 to 8 ring atoms, a heterocyclyl group having 3 to 8 ring atoms, an aryl group having 5 to 20 ring atoms, or a aryl group having 5 to 10 ring atoms. The heteroaryl group includes, but is not limited to, the alkyl group having 1 to 6 C atoms, the cycloalkyl group having 3 to 8 ring atoms, the heterocyclyl group having 3 to 8 ring atoms, the aryl group having 5 to 20 ring atoms, and the heteroaryl group having 5 to 10 ring atoms, which are further substituted with one or more of the following groups: 1-6 An alkyl group, a cycloalkyl group having 3 to 8 ring atoms, a heterocyclyl group having 3 to 8 ring atoms, a halogen group, a hydroxy group, a nitro group, or an amino group.

[0031] In the present invention, a site for which a conformation is not specified should be understood to include multiple conformations that may exist stably.

[0032] "Alkyl group" refers to a saturated aliphatic hydrocarbyl group, including linear and branched groups. C1-C6 alkyl group refers to an alkyl group containing 1 to 6 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1 3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, and 2,3-dimethylbutyl. C 1-C4 An alkyl group refers to an alkyl group containing 1 to 4 carbon atoms. 1 -C 4 Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, and s-butyl. The alkyl group may be substituted or unsubstituted, and if substituted, the substituent may be substituted at any available bonding site.

[0033] "Cycloalkyl group" refers to a monocyclic or polycyclic saturated or partially unsaturated cyclic hydrocarbyl substituent. A 3-8 membered cycloalkyl group refers to one containing 3 to 8 carbon atoms. In one embodiment, the 3-8 membered monocyclic cycloalkyl group includes a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclopentenyl group, a cyclohexyl group, a cyclohexenyl group, a cyclohexadienyl group, a cycloheptyl group, a cycloheptatrienyl group, a cyclooctyl group, and the like. A polycyclic cycloalkyl group includes a spiro ring, a condensed ring, and a bridged ring cycloalkyl group. The cycloalkyl group may be substituted with one or more optionally selected substituents.

[0034] The term "heterocyclyl group" refers to a monocyclic or polycyclic saturated or unsaturated cyclic hydrocarbon substituent, in which one or more ring atoms are selected from the heteroatoms nitrogen, oxygen, or S(O)m (where m is an integer of 0 to 2), preferably nitrogen or oxygen heteroatoms, but does not include the ring moiety of -OO-, -OS-, or -SS-, and the remaining ring atoms are carbon. A 4-10 membered heterocyclyl group refers to one containing 4 to 10 ring atoms, of which 1 to 3 are heteroatoms; the ring of the heterocyclyl group preferably contains 5 to 6 ring atoms, of which 1 to 2 are heteroatoms. In one embodiment, examples of the monocyclic heterocyclyl group include a dihydrofuryl group, a tetrahydrofuryl group, a pyrrolidinyl group, a piperidyl group, a piperazinyl group, a morpholinyl group, a morpholinothio group, and a homopiperazinyl group.

[0035] The term "aryl group" refers to an all-carbon monocyclic or fused polycyclic (i.e., rings sharing adjacent pairs of carbon atoms) group having a conjugated π-electron system, preferably 6-10 membered, more preferably phenyl and naphthyl, and most preferably phenyl. The aryl ring may be fused to a heteroaryl, heterocyclyl, or cycloalkyl ring, and the aryl group may be substituted or unsubstituted.

[0036] "Heteroaryl group" refers to an aryl group containing a heteroatom, of which the heteroatom includes an oxygen atom, a sulfur atom, and a nitrogen atom. Heteroaryl groups are preferably 5- or 6-membered, such as furyl, thienyl, piperidyl, pyrrole, N-alkylpyrrole, pyrimidinyl, pyrazinyl, imidazolyl, and tetrazolyl groups. The ring of the heteroaryl group may be condensed to the ring of an aryl group, a heterocyclyl group, or a cycloalkyl group, and the ring bonded to the parent structure is a heteroaryl ring. The heteroaryl group is a group selected from those that are optionally substituted or unsubstituted.

[0037] In the present invention, the "amino group" as a substituent includes primary, secondary and tertiary amino groups, specifically, -NR16 R 17 Among them, R 16 sum R 17 is a hydrogen atom or an arbitrarily selected group, such as H, a substituted or unsubstituted linear alkyl group, a substituted or unsubstituted branched alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group.

[0038] A "silyl group" refers to -Si(alkyl)3, where the three alkyl groups bonded to the silicon can be the same or different.

[0039] What is a cyclic lactam group? [ka] The number of ring-constituting atoms contained in ring A is not particularly limited, but may be a 5-membered ring, a 6-membered ring, etc., and examples thereof include glutarimide and succinimide. The abbreviations used in the present invention are as follows:

[0040] [Table 1]

[0041] According to one embodiment of the present invention, there is provided an intermediate having a structure represented by formula (IVa-1), formula (IVa-2), formula (IVa-3), formula (IVa-4), formula (IVa) or formula (IVa').

[0042] [ka]

[0043] During the ceremony, [ka] represents the structure produced by reacting a dihydroxy group with a first reagent and a second reagent; [ka] represents the structure formed by reacting dihydroxy with the first reagent; The first reagent is a borate ester or boric acid; The second reagent is a chiral amino alcohol, a chiral amino acid, a chiral amino acid ester, or a chiral diol; W is O or NH x where X is 0, 1 or 2; R 1 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocycloalkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group; R 2 and R 3 are each independently a hydrogen atom or a protecting group for an amino group, R 2 and R 3 is the above R 2 and R 3 can form a cyclic lactam group together with the nitrogen atom bonded to the amino group; among these, protecting groups for the amino group include, but are not limited to, -Boc, -Cbz, -Ac, -Ts, -Ms, -Bz, -Bn, -PMB, or a Schiff base.

[0044] R 4 -COOR 5 , -CONR 6 (i.e. CONHR 6 ) or -CN; Z is a hydrogen atom or a leaving group; examples of the leaving group include halogens (e.g., Cl, Br, I), OSO n R 9 , O.C.O.R. 10 Or OPO 2 R 11 Including, but not limited to; 9 , R 10 or R 11 are each independently -CF 3, an alkyl group, a phenyl group, or a phenyl group substituted with an alkyl group (eg, a tolyl group), n is 0, 1 or 2, and the silyl group may be an organosilyl group, or the like.

[0045] Y is O or absent.

[0046] In one embodiment, R 1 is C 1-6 an alkyl group, a 3- to 8-membered cycloalkyl group, a 3- to 10-membered aryl group, a 3- to 10-membered heteroaryl group, TMS, TBS, or -CH 2 X is a leaving group. In one embodiment, R 1 is C 1-6 In one embodiment, R is selected from an alkyl group, a cyclopropyl group, a phenyl group, a piperidyl group, TMS, TBS, or -CHX; X is a leaving group. 1 is a methyl group.

[0047] R 5 and R6 are each independently a hydrogen atom or a substituted or unsubstituted C 1-20 It is an alkyl group. 1-20 If the alkyl group is further substituted, the substituents are C 1-6 An alkyl group, a 3- to 8-membered cycloalkyl group, a 3- to 10-membered aryl group, a 3- to 10-membered heteroaryl group, a hydroxy group, a halogen, an amino group, a cyano group, or a C 1-4 It may be an alkoxy group.

[0048] In addition, R 5 and R 6 are each independently a hydrogen atom or a substituted or unsubstituted C alkyl group. 1-6 If the alkyl group is further substituted, the substituents are C 1-4 An alkyl group, a 3- to 8-membered cycloalkyl group, a 3- to 10-membered aryl group, a 3- to 10-membered heteroaryl group, a hydroxy group, a halogen, an amino group, a cyano group, or a C 1-4 It may be an alkoxy group.

[0049] In one embodiment, R 4 is -CN.

[0050] In one embodiment, Y is absent and Z is a hydrogen atom, R 4 is a cyano group, R 1 is a methyl group.

[0051] In addition, [ka] In R8 The group is determined by the boronic acid ester selected; 8 is a substituted or unsubstituted alkyl group; 8 is a substituted or unsubstituted C 1-10 Alkyl group or substituted or unsubstituted C 3-10 is a cycloalkyl group; 8 is a substituted or unsubstituted C 1-8 Alkyl group or substituted or unsubstituted C 3-8 is a cycloalkyl group; 8 is a substituted or unsubstituted C 1-6 Alkyl group or C 3-6 is a cycloalkyl group; In addition, the borate ester in the present invention may be any acceptable borate ester reagent in the art; in one embodiment, the borate ester is selected from trimethyl borate, triethyl borate, triisopropyl borate, or pinacol isopropoxyboronate; the chiral amino alcohol in the present invention may be any acceptable chiral amino alcohol in the art; in one embodiment, the chiral amino alcohol is selected from L-phenylglycinol, L-prolinol, L-phenylalaninol, (S)-α,α-diphenylprolinol, quinine, or cinchonine to obtain a product of desired configuration with higher ee value and yield. The chiral amino acid in the present invention may be any acceptable chiral amino acid in the art; in one embodiment, the chiral amino acid is selected from L-phenylalanine, L-alanine, L-proline, L-leucine, L-valine, L-phenylglycine, etc. The chiral amino acid ester in the present invention may be any acceptable chiral amino acid ester in the art; in one embodiment, the chiral amino acid ester is selected from L-phenylalanine ester, L-alanine ester, L-proline ester, L-leucine ester, L-valine ester, L-phenylglycine ester, etc., and the selected ester may be an alkyl ester or an aryl ester; the chiral diol in the present invention may be any acceptable chiral diol in the art; in one embodiment, the chiral diol is a diol containing a chiral structure of 1,2-diol or 1,4-diol; and the chiral diol is selected from chiral BINOL, chiral hydrobenzoin, (trans)-9,10-dihydroxy-9,10-dihydrophenoxanthrene, or (cis)-9,10-dihydroxy-9,10-dihydrophenoxanthrene, etc.

[0052] In addition, in order to achieve a better resolution effect, the second reagent is preferably a chiral amino alcohol.

[0053] In one embodiment, [ka] teeth [ka] having the structure of; [ka] has the following structure:

[0054] [ka]

[0055] Here, R 20 and R 21 A carbon atom bonded to R 22 and R 23 At least one carbon atom among the carbon atoms bonded to is a chiral carbon; R 20 and R 21 , R 22 , R 23 each independently represents H, substituted or unsubstituted C 1-6 selected from an alkyl group, a substituted or unsubstituted phenyl group, a substituted or unsubstituted naphthyl group, or a substituted or unsubstituted quinolyl group; R 24 and R 25 are each independently selected from H, a substituted or unsubstituted C1-6 alkyl group, or a substituted or unsubstituted phenyl group; R 23 and R 24 can be linked together to form a ring structure; R 23 , R 24 and R 25 can be linked together to form a bridged ring structure.

[0056] In the present invention, the "cyclic structure" includes a monocycle (such as an aromatic ring or a heterocycle), a spirocycle, and a bridged ring. In one embodiment, R20 and R 21 , R 22 , R 23 are each independently H, a phenyl group, or C 1-6 quinolyl groups substituted with alkyl or alkoxy groups; In one embodiment, R 24 and R 25 are independently H, C 1-6 selected from an alkyl group or a phenyl group; In one embodiment, R 23 and R 24 can be linked together to form a five-membered nitrogen-containing heterocycle; In one embodiment, R 23 and R 24 , R 25 are combined with each other [ka] It is possible to form a structure.

[0057] In one embodiment, [ka] teeth [ka] It is.

[0058] The present invention also provides a method for preparing said intermediate, comprising the steps of:

[0059] The compound to be resolved, the first reagent, the second reagent, and an aprotic solvent are mixed and heated under reflux. After the reaction is completed, the intermediate having the structure represented by formula (IVa-1) or formula (IVa-2) is crystallized to obtain the intermediate; the compound to be resolved is a mixture of formula (IVa) and formula (IVa'); [ka] It should be understood that the reaction process of the reaction is not a limitation of the present invention. The reaction is carried out by first reacting the compound to be resolved with a first reagent to produce a mixture of structures represented by formula (IVa-3) and formula (IVa-4), and then reacting the mixture of structures represented by formula (IVa-3) and formula (IVa-4) with a second reagent to obtain an intermediate of a structure represented by formula (IVa-1) or formula (IVa-2). Here, it should be understood that the mixture of structures represented by formula (IVa-3) and formula (IVa-4) may or may not be separated, and is within the scope of the present invention.

[0060] The reaction further includes the following steps: S001: Dissolve the compound to be resolved in an aprotic solvent; Furthermore, in step S001, the aprotic solvent is one or more aprotic solvents selected from tetrahydrofuran (THF) and 2-methyltetrahydrofuran (2-MeTHF), acetonitrile (ACN), toluene, benzene, 1,4-dioxane, and acetone, which increases the solubility difference between intermediates of different configurations and precipitates the intermediate of desired configuration (formula (IVa-1)) as a precipitate, further reducing the difficulty of separation and at the same time improving the yield and ee value of the product; further, the aprotic solvent is preferably acetonitrile.

[0061] Additionally, add 1-100 mL of aprotic solvent per gram of compound to be resolved; additionally, add 20-80 mL of aprotic solvent per gram of compound to be resolved; additionally, add 30-60 mL of aprotic solvent per gram of compound to be resolved.

[0062] S002: Add the first and second reagents, heat to reflux and react for a predetermined time; By adding the first and second reagents, a new chiral center is introduced into the diastereomer, a pair of diastereomers is obtained, and the separation can be realized by crystallization; the formula (IVa-1) obtained by this method is an important intermediate for the preparation of L-erythro-biopterin compounds, and can be precipitated as a solid in almost all common aprotic solvents, which can greatly reduce the difficulty of separation and improve the ee value of the product; for example, when using boric acid ester and chiral amino alcohol, the specific reaction mechanism is as follows:

[0063] [ka]

[0064] Also, the first reagent is a borate ester or boric acid; Also, the second reagent is a chiral amino alcohol, a chiral amino acid, a chiral amino acid ester, or a chiral diol; further, the second reagent is a chiral amino alcohol; The first and second reagents are as described above and will not be described in detail here. Further, examples of the borate ester include triisopropyl borate, examples of the chiral amino alcohol include L-prolinol, and examples of the solvent include acetonitrile.

[0065] In addition, the molar ratio of the compound to be resolved to the boric acid ester is 1 or less; Also, the molar ratio of the first reagent to the second reagent is 1:(1.0-1.3); Also, the molar ratio of the first reagent to the second reagent is 1:1; In addition, in step S002, the order of adding the reagents is not particularly limited, but it should be understood that this is not a limitation of the present invention. For example, the first reagent may be added first and then the second reagent may be added, or the first and second reagents may be added simultaneously. In addition, the reaction time order in step S002 is not particularly limited, and may be adjusted depending on the type of reagent used, and it should be understood that this is not a limitation of the present invention. In step S002, the first reagent is added first, and the reaction is allowed to proceed for 25 to 50 minutes. After that, the second reagent is added, and the reaction is allowed to proceed for 8 to 24 hours; S003: Upon crystallization, an intermediate having a structure represented by formula (IVa-1) or formula (IVa-2) is obtained; It should be understood that the crystallization can be performed by existing methods, and the temperature of solid-liquid separation during crystallization can be adjusted according to the specific solvent selected, which is not a limitation of the present invention; in one embodiment, crystallization is performed by the following method: after the reaction is completed, the temperature of the reaction liquid is lowered, and the solid precipitates and undergoes solid-liquid separation, and the product having the desired configuration is a solid-phase product or a liquid-phase product.

[0066] The method for producing the intermediate having the structure represented by the general formula (IVa-1) or (IVa-2) has the following advantages.

[0067] The intermediates having the structure represented by general formula (IVa-1) or (IVa-2) have different solubilities in aprotic solvents, so only crystallization is required. One of the intermediates having the structure represented by general formula (IVa-1) or (IVa-2) can be dissolved in a solvent and precipitated by precipitation, thus achieving the separation of products of different configurations through simple solid-liquid separation, which effectively reduces the difficulty of separation and is particularly suitable for industrialized production; The resolution reagent group consisting of the first and second reagents has mild conditions and low requirements for the quality purity of the substrate. After resolution, the ee value, dr value and purity of the product are extremely high. Resolution can be achieved even if the purity of the compound to be resolved is 70%, and at the same time, the purity of the obtained product can reach 99%, effectively achieving the effect of one-pot resolution and purification.

[0068] The intermediate having the structure represented by formula (IVa-1) or formula (IVa-2) obtained by the above method can be directly used in the next reaction step without dissociation, and the ee value and dr value can be further improved by the next synthesis step. After the experiment, when the product with 88% ee (IVa-1 / IVa-2=94 / 6) is used for the next reaction, the ee of the final product can still be improved to more than 99.9%, and the chiral purity can be comparable to the effect of introducing natural chiral; The obtained intermediate having a structure represented by formula (IVa-1) or formula (IVa-2) is a solid, has a stable structure, and can be easily quality-controlled and produced, and can be easily stored and transported.

[0069] The present invention further relates to a group of chiral resolution reagents, including a first reagent and a second reagent, wherein the first reagent is a boric acid ester or boric acid; the second reagent is a chiral amino alcohol, a chiral amino acid, a chiral amino acid ester or a chiral diol; among which, as mentioned above, said reagents will not be described in detail here.

[0070] The present invention further relates to a group of chiral resolving agents consisting of chiral amino alcohols and boric acid esters.

[0071] Moreover, the chiral resolution reagent group is composed of boric acid esters and L-proline. Furthermore, the chiral resolution reagent group is composed of boric acid esters and L-phenylglycinol. Furthermore, the chiral resolution reagent group is composed of boric acid esters and (S)-α,α-diphenylprolinol. Furthermore, the chiral resolution reagent group is composed of boric acid esters and quinine. Furthermore, the chiral resolution reagent group is composed of boric acid esters and cinchonine.

[0072] The present invention further relates to the application of said chiral resolution reagents in the preparation of L-erythro-biopterin compounds.

[0073] According to one embodiment of the present invention, the L-erythro-biopterin compound is mainly produced from a compound represented by formula (II) or a compound represented by formula (III) by dihydroxylation reaction, wherein the L-erythro-biopterin compound has a structure represented by formula (I): [ka] wherein Y is O or absent; in one embodiment, Y is absent.

[0074] Z is a hydrogen atom or a leaving group; the leaving group is, for example, a halogen (e.g., Cl, Br, I), OSO n R 9 , O.C.O.R. 10 Or OPO 2 R 11 Including, but not limited to; 9 , R 10 or R 11 are each independently -CF 3 , an alkyl group, a phenyl group, or a phenyl group substituted with an alkyl group (eg, a tolyl group), n is 0, 1 or 2, and the silyl group may be an organosilyl group, or the like.

[0075] R 1 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocycloalkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group; R 2 and R 3 are each independently a hydrogen atom or an amino-protecting group, where the amino-protecting group includes, but is not limited to, -Boc, -Cbz, -Ac, -Ts, -Ms, -Bz, -Bn, -PMB, or a Schiff base.

[0076] And R 2 and R 3 is R 2 and R 3Together with the nitrogen atom attached to R, R can form a cyclic lactam group, such as glutarimide, succinimide, etc. 2 and R3 do not necessarily form a cyclic lactam group together with the nitrogen atom to which they are attached, but may be selected as desired.

[0077] R 4 -COOR 5 , -CONR 6 or -CN; in one embodiment, R 4 is -CN.

[0078] R 5 and R 6 each independently represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocycloalkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group.

[0079] The method for producing L-erythro-biopterin compounds is innovative in that it uses olefin compounds represented by formula (II) or (III) as raw materials, constructs dihydroxyl of desired configuration through dihydroxylation reaction, effectively avoids the use of intermediates such as 5-deoxy-L-arabinose (D), and thereby avoids the use of ethanethiol with a foul odor, effectively reduces environmental pollution, and is environmentally friendly. Furthermore, the dihydroxylation reaction of olefins has relatively mild conditions, is simple to operate, has a high yield, and is easy to obtain raw materials having the structure represented by formula (II) or formula (III), greatly shortens the reaction path, further improves efficiency, reduces production costs, and is suitable for industrialized production.

[0080] It should be understood that it is within the scope of the present invention to simultaneously carry out the reaction described in the present invention and convert the raw material into the desired compound (the compound represented by formula (II) or the compound represented by formula (III)) by a common reaction in the art (e.g., oxidation reaction, reduction reaction, etc.), and to carry out the subsequent reaction as is, regardless of whether the desired compound (the compound represented by formula (II) or the compound represented by formula (III)) is separated or not. For example, [ka] (R 4 (-CHO) is cyclized, and before or during the cyclization reaction, an oxidizing agent is added to convert the aldehyde group to a carboxylic acid or carboxylic acid ester, and then the cyclization reaction is carried out. 4 is understood to be equivalent to the technical program as a carboxylic acid or carboxylic acid ester, and is understood to be within the scope of the present invention whether or not a compound containing a carboxylic acid or a carboxylic acid ester is isolated.

[0081] In one embodiment, R 1 is C 1-6 an alkyl group, a 3- to 8-membered cycloalkyl group, a 3- to 10-membered aryl group, a 3- to 10-membered heteroaryl group, TMS, TBS, or -CH 2 X is a leaving group. In one embodiment, R 1 is C 1-6 Alkyl group, cyclopropyl group, phenyl group, piperidyl group, TMS, TBS, or -CH 2 X is a leaving group. In one embodiment, R 1 is a methyl group.

[0082] R 5 and R 6 each independently represents a hydrogen atom or a substituted or unsubstituted C 1-20 is an alkyl group, where C 1-20 If the alkyl group is further substituted, the substituents are C 1-6An alkyl group, a 3- to 8-membered cycloalkyl group, a 3- to 10-membered aryl group, a 3- to 10-membered heteroaryl group, a hydroxy group, a halogen, an amino group, a cyano group, or a C 1-4 It may be an alkoxy group.

[0083] R 7 -OH or -NH 2 R 7 Ha-NH 2 If R 7 It is possible to obtain a compound in which is -OH.

[0084] The term "dihydroxylation reaction" refers to a reaction in which the double bond site of an olefin (e.g., in the formula (II) or (III)) is substituted with a hydroxyl group. [ka] ) to produce an o-dihydroxylated compound, which should be understood as a common reaction in the art. The dihydroxylation reaction method includes the Sharpless asymmetric dihydroxylation reaction, basic KMnO 4 The dihydroxylation reaction of the asymmetric dihydroxylation reaction of the formula (II) or the formula (III) can be used as a reactant, but is not limited to the dihydroxylation reaction of the formula (II) or the formula (III) of the asymmetric dihydroxylation reaction of the formula (III) or ...

[0085] In addition, the olefin group ( [ka] ) may be in either a cis or trans configuration.

[0086] In this reaction, the compound represented by formula (II) or formula (III) may be a pure substance, i.e., a compound represented by formula (II) or formula (III) containing only a cis structure, or a compound represented by formula (II) or formula (III) containing only a trans structure, or may be a mixture, i.e., a mixture consisting of a cis structure and a trans structure, and is not particularly limited here (a compound represented by formula (II) using a cis structure is preferred), and they are separated by chiral separation after the reaction, and the method of chiral separation is not particularly limited and may be an existing separation method. The compound represented by formula (II) is subjected to a dihydroxylation reaction and then a cyclization reaction to obtain an L-erythro-biopterin compound represented by (I). Here, the cyclization reaction can be performed by an existing method, for example, Journal of Organic Chemistry 1987, 52(18), 3997-4000 and Journal of Organic Chemistry 1988, 53(1), 35-38, etc.

[0087] 1. Preparation of L-erythrobiopterin compounds using the compound represented by formula (II) 1.1 Production of L-erythro-biopterin compounds using cis-olefins When the olefin in the compound represented by formula (II) has a cis structure, the process for producing the L-erythro-biopterin compound represented by formula (I) using the compound represented by formula (II) includes the following steps.

[0088] S111: The compound represented by formula (IIa) is subjected to a dihydroxylation reaction to obtain the compound represented by formula (IVa).

[0089] [ka]

[0090] Here, the dihydroxylation reaction in step S111 is a Sharpless asymmetric dihydroxylation reaction, a basic KMnO 4dihydroxylation, Fe-catalyzed vicinal oxylation or asymmetric epoxidation followed by hydrolysis to open the ring, preferably using the Sharpless asymmetric dihydroxylation reaction.

[0091] 1 When the reaction is carried out by Sharpless asymmetric dihydroxylation reaction, step S111 may include the following steps: mix the compound represented by formula (IIa) with an oxidizing agent, a bissiloxylation reagent, an alkali, and a ligand, react, and quench the reaction after the reaction is completed, and separate to obtain the compound represented by formula (IVa) (R, S). The reaction is preferably carried out at 0-25°C, and after the reaction is completed, the reaction can be quenched with sodium sulfite. After quenching, filter out the insoluble matter, take the organic phase, and perform chiral separation of the organic phase to obtain the compound represented by formula (IVa) (R, S) having homochirality.

[0092] The preferred bissiloxylation reagent is OsO 4 , K 2 OsO 4 , OsO 4 Hydrate and K 2 OsO 4 hydrates; the oxidizing agent is selected from one or more of K 3 [Fe(CN) 6 ] or NMO; the alkali is selected from one or more of potassium carbonate, sodium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate, NaOH, KOH, LiOH, NH 4 OH, t-BuONa, t-BuOK, t-BuOLi, cesium carbonate, triethylamine, diisopropylethylamine, DBU, pyridine and 4-dimethylaminopyridine; the ligand is selected from (DHQ) 2 PHAL, (DHQD) 2 the solvent being one or more of acetone, methanol, ethanol, 1,4-dioxane, tert-butyl alcohol and THF;

[0093] In addition, an osmate hydrolysis reagent may be added in step S111, and the osmate hydrolysis reagent includes, but is not limited to, methanesulfonamide.

[0094] Also preferably, the dosage ratio of the compound represented by formula (IIa) to the solvent is 1 g:(10-100 mL); the molar ratio of the compound represented by formula (IIa) to the oxidizing agent is 1:(0.1%-20%); the molar ratio of the compound represented by formula (IIa) to the alkali is 1:(1-10); and the molar ratio of the compound represented by formula (IIa) to methanesulfonamide is 1:(1-10).

[0095] 2 When the reaction is carried out by Sharpless asymmetric dihydroxylation reaction, step S111 may include the following steps: mixing the compound represented by formula (IIa), a bissiloxylation reagent, an alkali, and a solvent, reacting them, and after the reaction is completed, performing chiral separation to obtain the product.

[0096] The preferred bissiloxylation reagent is KMnO 4 Alkali includes potassium carbonate, sodium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate, NaOH, KOH, LiOH, NH 4 OH, t-BuONa, t-BuOK, t-BuOLi, cesium carbonate, triethylamine, diisopropylethylamine, DBU, pyridine, and 4-dimethylaminopyridine; and solvents, such as one or more of acetone, methanol, ethanol, 1,4-dioxane, tert-butyl alcohol, and THF.

[0097] When the reaction is carried out by a vicinaloxylation reaction using a 3 Fe catalyst, step S111 may include the following steps: mixing the compound represented by formula (IIa), a vicinaloxylation reagent, a catalyst, and a solvent, reacting them, and after the reaction is completed, performing chiral separation to obtain the product. Preferably, the bissiloxylation reagent includes hydrogen peroxide; the catalyst includes Fe(ClO 4 )2 , Fe(OTf) 2 , FeCl 2 and FeBr 2 the solvent being one or more of acetone, methanol, ethanol, 1,4-dioxane, tert-butyl alcohol and THF.

[0098] 4 If the reaction is carried out by epoxidation reaction, step S111 may include the following steps: reacting the compound represented by formula (II) with an epoxidation reagent to obtain an epoxidized intermediate, followed by ring-opening by adding an acid or alkali and chiral separation to obtain the required bissiloxylated product.

[0099] Preferably, the epoxidation reagent is one or more of m-CPBA, DMDO, and salen-Mn(III) / NaOCl; the solvent is one or more of dichloromethane, tetrahydrofuran, 1,4-dioxane, and tert-butyl alcohol. The acid used for ring opening may be dilute hydrochloric acid, dilute sulfuric acid, dilute phosphoric acid, etc., and the alkali used may be KHCO 3 , K 2 CO 3 , KOH, etc.

[0100] In addition, after the bissiloxylation reaction, the "chiral separation" may be performed by separation using a chiral column or a chemical resolution method, and the separation of the compound to be separated is preferably performed using a group of chiral resolution reagents, where the group of chiral resolution reagents includes a first reagent and a second reagent, the first reagent is a boric acid ester or boric acid; the second reagent is a chiral amino alcohol, a chiral amino acid, a chiral amino acid ester or a chiral diol; among them, as mentioned above, the reagents will not be described in detail here;

[0101] Furthermore, step S111 includes the following steps.

[0102] S1111: A compound represented by formula (IIa) is subjected to a dihydroxylation reaction to obtain a compound to be resolved, which is composed of compounds represented by formula (IVa) and formula (IVa'); [ka]

[0103] The dihydroxylation reaction is as described above and will not be described in detail here.

[0104] S1112: The compound to be resolved is resolved using a group of chiral resolution reagents to obtain a compound represented by formula (IVa-1); Here, the group of chiral resolution reagents in step S1112 includes a first reagent and a second reagent, and the first reagent is a borate ester or boric acid; the second reagent is a chiral amino alcohol, a chiral amino acid, a chiral amino acid ester, or a chiral diol; specifically, the resolution method in step S1112 is a method for producing an intermediate having a structure represented by the formula (IVa-1) or formula (IVa-2), and will not be described in detail here.

[0105] S112: [ka] and / or [ka] By subjecting the salt to an epoxidation reaction, an L-erythro-biopterin compound represented by formula (I) can be obtained.

[0106] Specifically, the L-erythro-biopterin compound represented by formula (I) can be produced according to the following steps S112a and S112b.

[0107] S112a: A compound represented by formula (IVa) [ka] and / or [ka] By subjecting the salt to an epoxidation reaction, an L-erythro-biopterin compound represented by formula (I) can be obtained.

[0108] [ka] S112b: A compound represented by formula (IVa-1) [ka] and / or [ka] By subjecting the salt to an epoxidation reaction, an L-erythro-biopterin compound represented by formula (I) can be obtained.

[0109] [ka]

[0110] E is halogen, C 1-4 Alkoxy group, C 1-4 Alkylthio group or -NH 2 and E includes a methoxy group, a chlorine atom, a methylthio group, or -NH2; The compound represented by formula (IVa-1) can rapidly release the compound represented by formula (IVa) into a protic solvent, [ka] and / or [ka] Since the solvent used in the epoxidation reaction with the salt is a protic solvent, the compound represented by formula (IVa-1) can directly participate in the subsequent reaction without dissociation, which effectively reduces the difficulty of operation and reduces the cost. Furthermore, the ee value of the product with the desired configuration can be improved by the cyclization reaction, and the product has a wide range of applications.

[0111] In step S112b, the compound represented by formula (IVa-1) is used as it is in the subsequent reaction, but it should be understood that this is not a limitation of the present invention. Similarly, the compound represented by formula (IVa-1) is first treated with a protic solvent to obtain the compound represented by formula (IVa), which is then subjected to the subsequent reaction, and the operation is the same as in step S112a.

[0112] In step S112b [ka] Salt is [ka] The term "salt" refers to a salt containing the compound represented by the formula (I) and may be a salt acceptable in the art, such as a hydrochloride salt. [ka] and / or [ka] It is to be understood that the salts may contain protecting groups which are acceptable in the art and are within the scope of the present invention.

[0113] Step S112a is almost the same as S112b, except that the compound represented by formula (IVa) is used instead of the compound represented by formula (IVa-1) in step S112b. Step S112b will be described in more detail below as an example.

[0114] Furthermore, step S112b includes the following steps:

[0115] S1121: Cyclization step. A compound represented by formula (IVa-1), [ka] and / or [ka] The salt, alkali and solvent are mixed and heated to 50-100° C. After the reaction is completed, the mixture is cooled and a solid is precipitated. The solid is filtered to obtain a solid (that is, a compound represented by formula (I-1)).

[0116] [ka]

[0117] Y, Z, R 1 , R 2 , R 3 , R 4 The definition of is as above and will not be described in detail here. R7 is -OH or -NH2.

[0118] Further, the cyclization process includes the steps of adding Na to MeOH and stirring until complete reaction; [ka] and / or [ka] Add salt and N 2 Stir at room temperature for a predetermined time (preferably 3-10 min), filter insoluble matter in the system, add the compound represented by formula (IVa-1), heat to reflux, and after the reaction is completed, cool to room temperature, stir for 40-80 min, and filter the precipitated solid matter. In the cyclization step, the solvent may be a protic solvent, preferably an alcohol solvent, including but not limited to one or more of methanol, ethanol and isopropanol. The alkali may be one or more of sodium ethylate, sodium methylate, t-BuONa, t-BuOK and t-BuOLi; preferably a strong base, such as sodium methylate. The compound represented by formula (IVa-1) and [ka] and / or [ka] The molar ratio of the salt is 1:(1-3); the molar ratio of the compound represented by formula (IVa-1) to the alkali is 1:(2-5); the mixing ratio of the compound represented by formula (IVa-1) to the solvent is 1 g:(5-100 mL).

[0119] In the cyclization step, R 4 Woha-COOR 5 , -C ONR 6 or -CN raw materials, and innovatively [ka] and / or [ka] The salt is used to carry out cyclization to form the desired bicyclo ring, which has been first applied to the synthesis of biopterin compounds, which has significant advantages over traditional methods: high atom utilization rate, high conversion rate, and complete reaction; the by-products are soluble in the reaction solvent, and the products are insoluble and easy to purify; this process can obtain high purity products (98%-99%) by simply filtering the products and washing them easily; [ka] and / or [ka] The cost of the salt is relatively low, which can further reduce the production cost. However, in the conventional cyclization process, [ka] The raw material is acetylated 1,2-dichloro-1,2-diphenyl-2,3-diphenyl-1,2-diphenyl-2,4 ...

[0120] S1122: Hydrolysis step. The solid obtained in the cyclization step (i.e., the compound represented by formula (I-1)) is added to an alkaline solution, and after the reaction is completed, an acid is added to adjust the pH to 5 to 6. The precipitated crystals are filtered and dried to obtain the L-erythro-biopterin compound represented by formula (I).

[0121] [ka]

[0122] R 1 The definition of is as above and will not be explained in detail here. 7 -OH or -NH 2 It is.

[0123] Furthermore, the hydrolysis process includes the following steps: suspending the compound represented by formula (I-1) in an alkaline solution, heating to 50-100°C, and stirring for 2h-5h; after cooling to room temperature, adding acid to adjust the pH to 5-6, filtering and drying the precipitated crystals to obtain the L-erythro-biopterin compound represented by formula (I).

[0124] Here, the alkaline solution may be an inorganic base solution, such as a sodium hydroxide solution or a potassium hydroxide solution, preferably a sodium hydroxide solution with a mass percentage of 5%-40%. The molar ratio of the compound represented by formula (I-1) to the alkali is preferably 1:(5-20), more preferably 1:(5-10). The acid may be an organic acid or an inorganic acid, such as formic acid, hydrochloric acid, sulfuric acid, hydrobromic acid, preferably formic acid.

[0125] In addition, R 4 -COOR 5 or -CONR 6 If so, the hydrolysis step may be omitted.

[0126] By treating the compound represented by formula (IVa-1), a compound represented by formula (IVa) is obtained, and the compound represented by formula (IVa) can be used as a catalyst. [ka] and / or [ka] Since the process of reacting the salt is almost the same as the above-mentioned method, it is only necessary to replace the compound represented by formula (IVa) with the compound represented by formula (IVa-1), and therefore, the detailed description will not be given here.

[0127] 1.2 Production of L-erythro-biopterin compounds using trans-olefins When the olefin in the compound represented by formula (II) has a cis structure, the process for producing the compound represented by formula (I) from the compound represented by formula (II) includes the following steps: S121: The compound represented by formula (IIb) is subjected to a dihydroxylation reaction to obtain the compound represented by formula (IVb-1) and / or formula (IVb-2).

[0128] [ka]

[0129] The dihydroxylation reaction in step S121 is the same as S111, and therefore will not be described in detail here.

[0130] S122: The compounds represented by formula (IVb-1) and / or formula (IVb-2) are subjected to an acetylation reaction to obtain compounds represented by formula (VIIb-1) and / or formula (VIIb-2).

[0131] [ka]

[0132] Here, the acetylation reaction in step S122 may include the following steps: The compound represented by formula (IVb-1) and / or formula (IVb-2), the acetylation reagent and p-toluenesulfonamide (PTSA) are dissolved in a solvent and stirred for 20 min-50 min, then water is added and stirring is continued, and after the reaction is completed, the compound represented by formula (VIIb-1) and / or formula (VIIb-2) is obtained by separation. Here, the acetylation reagent is one or more of acetic anhydride, trimethyl orthoacetate, and acetyl chloride. The solvent is acetonitrile and one or more of THF, dioxane, DCM, MTBE, etc.

[0133] S123: Compounds represented by formula (VIIb-1) and / or formula (VIIb-2) are subjected to Mitsunobu reaction to obtain compounds represented by formula (VIIb-3) and / or formula (VIIb-4).

[0134] [ka]

[0135] Specifically, the steps include: A compound represented by formula (VIIb-1) and / or formula (VIIb-2), a nucleophilic reagent [ka] , PPh 3 Or Bu 3 P, diisopropyl azodiformate (DIAD) or diethyl azodiformate (DEAD) are dissolved in a solvent and reacted, and after the reaction is completed, the desired product is obtained by separation. Specifically, the combination of reagents is DEAD / PPh 3 , DIAD / PPh 3 , DEAD / n-Bu 3 P or DIAD / n-Bu 3 These include, but are not limited to, P.

[0136] Here, R 10 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocycloalkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group; preferably R 10 is a substituted or unsubstituted aryl group, and if the aryl group is further substituted, the substituent is C 1-6 Alkyl group or C 1-6 More preferably, R 10 teeth [ka] And " [ka] " indicates the binding site.

[0137] R 11 is H, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocycloalkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group; preferably R 11 is H or C 1-6 It is an alkyl group.

[0138] In one embodiment, [ka] teeth [ka] (Naproxen).

[0139] S124: A compound represented by formula (VIIb-3) and / or formula (VIIb-4) [ka] and / or [ka] A cyclization reaction with a salt (preferably a guanidine salt) and hydrolysis are carried out to obtain an L-erythro-biopterin compound represented by formula (I).

[0140] [ka]

[0141] Step S124 is the same as step S112, so it will not be described in detail here. 1 , R 2 , R 3 , R 4 , R 10 The definition of is as above, and will not be explained in detail here. E is a halogen, C 1-4 Alkoxy group, C 1-4 Alkylthio group or -NH 2 and E is a methoxy group, a chlorine atom, a methylthio group, or -NH 2 Examples include; When the olefin in the compound represented by formula (II) has a cis structure, the product with the desired configuration can be obtained in two steps with high yield through dihydroxylation and cyclization, which can greatly shorten the reaction route, improve production efficiency, and reduce production costs. When the olefin in the compound represented by formula (II) has a trans structure, the dihydroxyl is first constructed by dihydroxylation to form two chiral centers, and then one hydroxyl group is acetylated by innovative and highly selective monoacetylation of O-diol, and the other hydroxyl group is chirally inverted by Mitsunobu reaction to obtain an intermediate with the desired configuration, and then the desired product is obtained by cyclization, which greatly expands the range of raw material selection and allows the selection of relatively cheap raw materials. In addition, the acetylation and Mitsunobu reactions and other processes have high yields, and the by-products of the monoacetylation reaction and the by-products that are not inverted in the Mitsunobu reaction can be recovered by simple hydrolysis and used again as raw materials, ensuring the economy of the entire route and meeting the requirements of industrialized production.

[0142] 2. Preparation of L-erythrobiopterin compounds using the compound represented by formula (III) The compound represented by formula (III) is obtained by a cyclization reaction from a commercially available raw material or a compound represented by formula (II). For example, [ka] and / or [ka] The cyclization reaction can be carried out using a salt.

[0143] 2.1 Production of L-erythro-biopterin compounds using cis-olefins In addition, when the olefin in the compound represented by formula (III) has a cis structure, the process for producing the L-erythro-biopterin compound represented by formula (I) using the compound represented by formula (III) includes the following steps: S211: The compound represented by formula (III) is subjected to a dihydroxylation reaction to obtain a compound represented by formula (I-1).

[0144] [ka]

[0145] The reagents and reaction conditions for the dihydroxylation reaction in step S211 are the same as those described in step S111, and will not be described in detail here.

[0146] In step S211, the compound to be resolved is separated using the chiral resolution reagent group, and the separation method and the chiral resolution reagent group are as described above. In step S111, the compound to be resolved is a compound to be resolved ( [ka] and [ka] and mixtures thereof) and are not described in detail herein and are within the scope of the present invention.

[0147] S212: The compound represented by formula (I-1) is hydrolyzed under basic conditions (such as conditions of sodium hydroxide) to obtain the L-erythro-biopterin compound represented by formula (I).

[0148] [ka]

[0149] Step S212 is the same as S1122, so it will not be described in detail here.

[0150] 2.2 Production of L-erythro-biopterin compounds using trans-olefins When the olefin in the compound represented by formula (III) has a trans structure, the compound represented by formula (III) is first subjected to a dihydroxylation reaction to form a dihydroxy, and then an acetylation reaction and a Mitsunobu reaction are carried out to obtain an intermediate having the desired configuration. The specific method and steps are the same as those in S121-S124, and therefore will not be described in detail here.

[0151] When the olefin in the compound represented by formula (III) has a cis structure, the dihydroxylation reaction can obtain a product with the desired configuration in high yield, greatly shortening the reaction route, improving production efficiency, and reducing production costs. When the olefin in the compound represented by formula (III) has a trans structure, the dihydroxylation reaction is first used to construct a dihydroxy and form two chiral centers, and then one hydroxyl group is acetylated by the innovative and highly selective monoacetylation reaction of O-diol, and the other hydroxyl group is chirally inverted by the Mitsunobu reaction and hydrolyzed to obtain the desired product, greatly increasing the range of raw material selection and allowing the selection of relatively cheap raw materials. In addition, the acetylation reaction and Mitsunobu reaction and other processes have high yields, and the by-products of the monoacetylation reaction and the by-products that are not inverted in the Mitsunobu reaction can be recovered by simple hydrolysis and used again as raw materials, ensuring the economy of the entire route and meeting the requirements of industrialized production.

[0152] 3. Preparation of the compound represented by formula (II) and the compound represented by formula (III) The compounds represented by formula (II) or formula (III) can be synthesized by conventional methods, such as Heck reaction (see J. Chem. Soc., Chem. Commun. 1983, 15, 793-794), Grignard reaction (see Chemistry Letters 2014, 43(6), 922-924), debromination reaction of alkyl lithium and reaction with allyl bromide (see Chemistry - An Asian Journal 2012, 7(5), 1061-1068), Stille reaction (see J. Org. Chem. 1990, 55, 3019), and Negishi coupling (see J. Chem. Soc., Chem. Commun. 1977, 683-684). It should be understood that the compounds may be commercially available raw materials and are within the scope of the present invention.

[0153] However, during the research, the applicants found that when the compound represented by formula (II) or formula (III) is prepared by Heck reaction, the cis-trans selectivity and region selectivity are low; the Grignard reaction can control the cis-trans structure, but it is necessary to generate more unstable phenylmagnesium bromide, which is difficult to industrialize; the debromination reaction of alkyllithium and the reaction with allyl bromide are strict conditions and the conversion rate is low; the Stille reaction involves a coupling reaction between an alkenyl tin reagent and a substrate, which requires the synthesis of highly toxic organotin, which is not suitable for industrialization; the Negishi coupling requires the production of more unstable and flammable organozinc reagent, which requires complicated post-treatment, which is not suitable for industrialization. In order to further improve the production efficiency and reduce the production cost, it is preferable to synthesize according to the following method.

[0154] 3.1 Synthesis of compounds of formula (II) 3.1.1 Synthesis of compounds represented by cis structural formula (II) When the olefin in the compound represented by formula (II) is a compound represented by formula (IIa) having a cis structure, the compound represented by formula (IIa) can be produced from the compound represented by formula (V) by catalytic hydrogenation; [ka]

[0155] Specifically, the steps include: The compound represented by formula (V), a catalyst and a solvent are mixed and reacted under a hydrogen gas atmosphere. After completion of the reaction, the mixture is filtered and concentrated to obtain the compound represented by formula (IIa) having a cis structure.

[0156] Here, the catalyst is selected from one or more of Lindlar's catalyst, palladium on carbon, Raney nickel, platinum black, and platinum oxide, and the solvent is selected from one or more of tetrahydrofuran, 2-methyltetrahydrofuran, ether, methyl tert-butyl ether, cyclopentyl methyl ether, methanol, ethanol, isopropanol, acetonitrile, and toluene.

[0157] Preferably, the ratio of the compound represented by formula (V) to the solvent is 1 g: (1-100 mL), more preferably 1 g: (5-60 mL). Preferably, the mass ratio of the compound represented by formula (V) to the catalyst is 1: 0.005-0.2, more preferably 0.01%-0.1. The pressure of the supplied hydrogen gas is 0.1-10 MPa, more preferably 0.1-5 MPa; the reaction temperature is preferably 0-50°C.

[0158] Here, the compound represented by formula (V) is a commercially available raw material and may be synthesized by an existing method, and is preferably synthesized according to the following method.

[0159] S311: The compound of formula (V) is prepared from the compound of formula (VI) by Sonogashira reaction: [ka]

[0160] where M is H or a leaving group; M is preferably a halogen, a sulfonate, a carboxylate or a phosphate, and leaving groups include halogens (e.g., Cl, Br, I), OSO n R 9 , O.C.O.R. 10 Or OPO 2 R 11 Including, but not limited to; 9 , R 10 Or R 11 are each independently -CF 3 , an alkyl group, a phenyl group, or a phenyl group substituted with an alkyl group (e.g., a tolyl group), n is 0, 1, or 2, and the silyl group may be an organosilyl group, etc. Here, examples of the sulfonic acid ester include methylbenzenesulfonate, methylsulfonyl, and trifluoromethanesulfonate. M is more preferably bromine.

[0161] When preparing the compound represented by formula (V) by the above reaction, the compound represented by formula (VI) which is widely available on the market can be used as the raw material, which significantly reduces the production cost. In addition, the reaction has a high yield (>95%), the reaction conditions are mild at room temperature, and the product can be obtained by conventional recrystallization.

[0162] Specifically, the steps include: S3111: Mixing a compound represented by formula (VI), a catalyst, a ligand, and a solvent; S3112: Alkaline and [ka] After the reaction is completed, the reaction is quenched and separated to obtain the compound represented by formula (V).

[0163] In the step S3111, the dissolution is preferably carried out at 0-35°C, the catalyst is preferably a combination of a copper catalyst and a palladium catalyst, and the ligand is a phosphine ligand. Here, the copper catalyst is one or more of cuprous chloride, cuprous bromide, and cuprous iodide, preferably cuprous iodide. The palladium catalyst is palladium chloride, palladium acetate, PdCl 2 (dppf), Pd 2 (dba) 3 , Pd(PPh 3 ) 4 One or more of the following.

[0164] In step S3111, the solvent is one or more of tetrahydrofuran, 2-methyltetrahydrofuran, ether, methyl tert-butyl ether, cyclopentyl methyl ether, and acetonitrile, and preferably 2-methyltetrahydrofuran. In step S3111, the alkali is one or more of potassium carbonate, sodium carbonate, cesium carbonate, triethylamine, diisopropylethylamine, DBU, pyridine, and 4-dimethylaminopyridine.

[0165] Also, the dosage ratio of the compound represented by formula (VI) to the solvent is preferably 1g:(1-20mL), preferably 1g:(5-15mL). The molar ratio of the compound represented by formula (VI) to the catalyst is 1:(1%-15%), preferably 1:(1%-10%). The molar ratio of the compound represented by formula (VI) to the ligand is preferably 1:(2%-30%), more preferably 1:(2-20%); the molar ratio of the compound represented by formula (VI) to the alkali is 1:(5-15).

[0166] 3.1.2 Synthesis of compounds represented by trans structural formula (II) In the case of a compound represented by formula (IIb) in which the olefin in the compound represented by formula (II) has a trans structure, the compound represented by formula (IIb) can be prepared from a compound represented by formula (VI) by a coupling reaction (e.g., Suzuki coupling reaction); [ka]

[0167] wherein M is H or a leaving group; preferably M is a halogen, a sulfonate, a carboxylate, or a phosphate, leaving groups including, but not limited to, halogen (e.g., Cl, Br, I), OSOnR9, OCOR10, or OPO2R11; R9, R10, or R11 are each independently -CF 3 , an alkyl group, a phenyl group, or a phenyl group substituted with an alkyl group (e.g., a tolyl group), n is 0, 1, or 2, and the silyl group may be an organosilyl group, etc. Here, examples of the sulfonic acid ester include methylbenzenesulfonate, methylsulfonyl, and trifluoromethanesulfonate. More preferably, M is bromine.

[0168] Specifically, the steps include: The compound represented by formula (VI), trans-1-propenylboronic acid reagent, catalyst, solvent, and ligand are mixed, and after the reaction is completed, the compound represented by formula (IIb) having a trans structure is obtained by separation.

[0169] In this case, the trans-1-propenyl boronic acid reagent refers to a boronic acid reagent containing trans-1-propenyl, and includes, but is not limited to, 4,4,5,5-tetramethyl-2-(2-methyl-1-propenyl)-1,3,2-dioxaborolane, trans-1-propenylboronic acid, or trans-1-allyl fluoroborate.

[0170] Also preferred catalysts include 5% Pd / C and 10% Pd / C, Pd(OAc) 2 , PdCl 2 (PPh 3 ) 2 , Pd(PPh 3 ) 4 , PdCl 2(dppf), PdCl 2 (MeCN) 2 , Pd 2 (dba) 3 The solvent is one or more of methanol, ethanol, isopropanol, butanol, water, tetrahydrofuran, 2-methyltetrahydrofuran, 1,4-dioxane, DME, DMF, DMSO, NMP, acetonitrile, dichloromethane, 1,2-dichloroethane, methyl acetate, isopropyl acetate, butyl acetate, ether, methyl tert-butyl ether, toluene, dimethylbenzene, acetone, methyl ethyl ketone, and methylcyclopentane. The ligand is PPh 3 , BINAP, dppf, Xantphos, Xphos monophosphine and diphosphine ligands.

[0171] Here, the compound represented by formula (VI) is a commercially available raw material and can be synthesized by conventional methods. The compound represented by formula (VI) is a pyrazine compound, which is a compound that is widely sold in the market at present, such as CAS: 6966-01-4, 612835-51-5, 17890-77-6, 17231-51-5, etc., and has low cost, which can further reduce the manufacturing cost of the entire process.

[0172] 3.2 Synthesis of compounds of formula (III) The compound of formula (III) may be prepared from commercially available raw materials or by conventional methods. The compound of formula (III) may be prepared from the compound of formula (II) by cyclization, i.e., first by cyclization and then by dihydroxylation, or by dihydroxylation followed by cyclization.

[0173] 3.2.1 Synthesis of compounds represented by cis structural formula (III) In the case of a compound represented by formula (IIIa) in which the olefin in the compound represented by formula (III) has a cis structure, the compound represented by formula (IIIa) can be produced from a compound represented by formula (VIII) by catalytic hydrogenation; [ka]

[0174] Specifically, the steps include: The compound represented by formula (VIII), a catalyst and a solvent are mixed and reacted under a hydrogen gas atmosphere. After completion of the reaction, the mixture is filtered and concentrated to obtain the compound represented by formula (IIIa) having a cis structure.

[0175] Here, the catalyst is one or more of Lindlar's catalyst, palladium / carbon, Raney nickel, platinum black, and platinum oxide; the solvent is one or more of tetrahydrofuran, 2-methyltetrahydrofuran, ether, methyl tert-butyl ether, cyclopentyl methyl ether, methanol, ethanol, isopropanol, acetonitrile, and toluene.

[0176] Preferably, the dosage ratio of the compound represented by formula (VIII) to the solvent is 1 g: (1-100 mL), more preferably 1 g: (5-60 mL); preferably, the mass ratio of the compound represented by formula (VIII) to the catalyst is 1: 0.005-0.2, more preferably 0.01%-0.1; the pressure of the supplied hydrogen gas is 0.1-10 MPa, preferably 0.1-5 MPa; the reaction temperature is preferably 0-50°C.

[0177] The compound represented by formula (VIII) is a commercially available raw material and may be prepared by a conventional method, preferably by the following method.

[0178] S3211: A compound represented by formula (V) can be obtained from a compound represented by formula (VI) by Sonogashira reaction.

[0179] [ka]

[0180] Specifically, the compound represented by formula (V) is prepared by the method of S3111-S3112, which will not be described in detail here.

[0181] S3212: A compound represented by formula (VIII) can be obtained from a compound represented by formula (V) by a cyclization reaction.

[0182] [ka]

[0183] Specifically, the cyclization reaction may be carried out by the following method: A compound represented by formula (V) [ka] and / or [ka] and cyclizing the compound with a salt (preferably a guanidine salt), [ka] and / or [ka] The salts are as described above and will not be described in detail here.

[0184] Also, in step S3212, the following steps are included: [ka] and / or [ka] The salt, alkali and solvent are mixed and heated to 50-100°C, and after the reaction is completed, the mixture is filtered to obtain the compound represented by formula (VIII). Here, the solvent includes an alcohol solvent, preferably one or more of methanol, ethanol and isopropanol; the alkali includes one or more of sodium ethylate, sodium methylate, t-BuONa, t-BuOK and t-BuOLi; and preferably a strong base, such as sodium methylate.

[0185] Also, step S3212 includes the steps of: adding Na to MeOH and stirring until completely reacted; [ka] and / or [ka] Add salt and N 2 Stir for 3-10 min at room temperature, filter the insoluble matter in the system, add the compound represented by formula (V), heat to reflux, cool to room temperature after the reaction is complete, stir for 40-80 min, filter the precipitated solid matter, and obtain the compound represented by formula (VIII).

[0186] 3.2.2 Synthesis of compounds represented by trans structural formula (III) When the olefin in the compound represented by formula (III) has a trans structure, the compound represented by formula (III) can be obtained by the following method.

[0187] S3221: A compound represented by formula (II) can be obtained from a compound represented by formula (VI) by a coupling reaction; [ka]

[0188] M is H or a leaving group; preferably M is a halogen, a sulfonate, a carboxylate, or a phosphate, where sulfonates include methylbenzenesulfonate, methylsulfonyl, trifluoromethanesulfonate, and the like; The coupling reaction in step S3221 is as described above and will not be described in detail here.

[0189] S3222: The compound represented by formula (II) can be cyclized to give the compound represented by formula (IIIb); [ka]

[0190] The cyclization reaction in step S3222 is as described above and will not be described in detail here.

[0191] 3. Preferred reaction pathway Route 1 [ka]

[0192] The definition of each substituent is as above, and will not be described in detail here. The method for producing the L-erythro-biopterin compound represented by formula (I) includes the following steps: (1) A compound represented by formula (VI) [ka] and Sonogashira reaction to obtain a compound represented by formula (V); (2) The compound represented by formula (V) is subjected to catalytic hydrogenation to obtain the compound represented by formula (IIa); (3) The compound represented by formula (IIa) can be subjected to a dihydroxylation reaction to give the compound represented by formula (IVa); preferably, chiral resolution is carried out using the chiral resolution reagent group, and the chiral resolution reagent group and resolution method are as described above.

[0193] (4) A compound represented by formula (IVa) or a compound represented by formula (IVa-1) ( [ka] ) is subjected to a cyclization reaction to obtain a compound represented by formula (I-1), and the compound represented by formula (I-1) is hydrolyzed to obtain an L-erythro-biopterin compound represented by formula (I).

[0194] In the above (1) to (4), the specific explanation of each reaction is as above, and will not be described in detail here. 4 -COOR 5 or -CONR 6 In this case, the hydrolysis step (4) may be omitted.

[0195] In this embodiment, the compound represented by (VI) is used as the starting material, and cross-coupling reaction with alkyne is carried out, followed by catalytic hydrogenation to obtain cis-olefin. Then, two chiral centers are constructed by innovative systematic dihydroxylation reaction, and then single enantiomer (R,S)-pyrazine propylene glycol compound is obtained by chiral separation and purification. Then, L-erythro-biopterin compound is obtained by cyclization reaction. This route greatly shortens the reaction route, and has high yield and high atom utilization rate in each step, avoiding the traditional condensation of 5-deoxy-L-arabinose and 2,4,5-triamino-6-hydroxypyrimidine (TAP) to produce L-erythro-biopterin, and completely overcomes the shortcomings of the traditional industrialized production method such as low efficiency, low yield, high cost, and high pollution.

[0196] Route 2 [ka]

[0197] (1) A compound represented by formula (VI) [ka] and Sonogashira reaction to obtain a compound represented by formula (V); (2) The compound represented by formula (V) is subjected to a cyclization reaction to obtain a compound represented by formula (VIII); (3) The compound represented by formula (VIII) is subjected to catalytic hydrogenation to obtain the compound represented by formula (III); (4) The compound represented by formula (III) can be subjected to a dihydroxylation reaction to obtain a compound represented by formula (I-1); (5) The compound represented by formula (I-1) is hydrolyzed under basic conditions to give the L-erythro-biopterin compound represented by formula (I).

[0198] In the above (1) to (5), the specific explanation of each reaction is as above, and will not be described in detail here. 4 -COOR 5 or -CONR 6 In this case, the hydrolysis step (5) may be omitted.

[0199] In this embodiment, the compound represented by (VI) is used as the starting material, and is cross-coupled with alkyne, followed by cyclization and catalytic hydrogenation to obtain the desired cis-olefin. After dihydroxylation, two chiral centers are constructed, and the desired L-erythro-biopterin compounds are obtained through chiral separation and purification. This route greatly shortens the reaction route, and has high yields and high atom utilization rates in each step, avoiding the traditional method of condensing 5-deoxy-L-arabinose and 2,4,5-triamino-6-hydroxypyrimidine (TAP) to produce L-erythro-biopterin, and completely overcomes the shortcomings of the traditional industrialized production method, such as low efficiency, low yield, high cost, and high pollution.

[0200] Route 3 [ka]

[0201] (1) A compound represented by formula (VI) is subjected to a coupling reaction to obtain a compound represented by formula (IIb); (2) The compound represented by formula (IIb) is subjected to a dihydroxylation reaction to obtain a compound represented by formula (IVb-1) and / or formula (IVb-2); (3) Acetylation of the compound represented by formula (IVb-1) and / or formula (IVb-2) gives a compound represented by formula (VIIb-1) and / or formula (VIIb-2); (4) The compound represented by formula (VIIb-1) and / or formula (VIIb-2) is subjected to a Mitsunobu reaction to obtain a compound represented by formula (VIIb-3) and / or formula (VIIb-4); (5) The compound represented by the formula (VIIb-3) and / or the formula (VIIb-4) [ka] and / or [ka] The L-erythro-biopterin compound represented by formula (I) is obtained by cyclization with a salt (preferably a guanidine salt) and hydrolysis.

[0202] In the above (1) to (4), the specific explanation of each reaction is as above, and will not be described in detail here. 4 -COOR 5 or -CONR 6 In this case, the hydrolysis step (5) may be omitted.

[0203] In the above method, the compound represented by (VI) is used as the starting material, and an olefin is constructed by a coupling reaction, and the olefin is innovatively subjected to a dihydroxylation reaction, an acetylation reaction, and a Mitsunobu reaction to obtain a product with a desired configuration. This route makes full use of the properties of each reaction, improves stereoselectivity, and expands the range of raw material selection. The by-product of the monoacetylation reaction and the by-product that is not inverted in the Mitsunobu reaction are recovered by simple hydrolysis and then used again as raw materials, ensuring the economic efficiency of the entire route. Moreover, the conventional method of producing L-erythro-biopterin by condensing 5-deoxy-L-arabinose with 2,4,5-triamino-6-hydroxypyrimidine (TAP) can be avoided, which can avoid environmental pollution and improve the safety of production. EXAMPLES

[0204] The present invention will be described in detail below with reference to specific examples.

[0205] Example 1 [ka]

[0206] Compound 8 200mg, CuI 11mg, PdCl 2 10mg,PPh 3 30 mg of the product was weighed out and placed in a 25 mL three-neck flask, and 5 mL of acetonitrile was added. While stirring at room temperature, 0.7 mL of triethylamine and 1.1 mL of propyne (1M in THF) were added, and the mixture was reacted and stirred for 16 h. 10 mL of water was added to quench the reaction, and the organic layer was dried and concentrated to obtain 163 mg of crude product of compound 6, which was used in the next reaction. IR (cm -1 ) ν 3400, 2226, 1647, 1487,1192; 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.26 (s, 1H), 7.54 (s, 2H), 2.01 (s, 3H), 13C NMR (101 MHz, DMSO) δ 155.61, 150.33, 128.08, 115.71, 111.16, 88.27, 76.62, 4.18. HRMS m / z (ESI+) C 8 H 7 N 4 + requires: 159.0667; found: 159.0671.

[0207] [ka]

[0208] 62 mg of Na was added to 10 mL of MeOH, stirred until complete reaction, and 226 mg of guanidinium hydrochloride was added and N 2 The mixture was stirred at room temperature for 5 min. The insoluble matter in the system was filtered, and 163 mg of compound 6 was added. The mixture was heated to reflux and stirred for 18 h. The reaction system was cooled to room temperature and stirred for 1 h. The yellow crystals precipitated in the system were filtered to give 144 mg of compound 5 (purity >99%, yield for two steps 71.6%); IR (cm -1 ) ν 3421, 3102, 1635, 1456,1507, 1063; 1 H NMR (500 MHz, DMSO-d6) δ 8.91 (s, 1H), 7.08 (s, 2H), 6.33 (s, 2H), 2.06 (s, 3H); 13 C NMR (125 MHz, DMSO) δ 163.83, 162.42, 155.36, 146.65 , 136.10, 119.12, 91.24, 83.52, 4.73. HRMS m / z (ESI+) C 9 H 9 N 6 + requires: 201.4358; found: 201.4359.

[0209] [ka]

[0210] Compound 5 (144 mg) was added to THF (20 mL), heated to 50° C. and dissolved, and Lindlar Pd (150 mg) was added. 2 The mixture was replaced with 1 atm and stirred for 3 days, the catalyst was filtered off, and the mixture was concentrated to give compound 4 (120 mg, purity 90%, yield 83%); IR (cm -1 ) ν 3294, 1646, 1508, 1479, 1380, 1046; 1 H NMR (500 MHz, DMSO) δ 8.49 (s, 1H), 7.28(d, J= 9.0 Hz, 1H), 7.07 (d, J = 9.5 Hz, 1H), 6.75 - 6.69 (m, 1H), 6.58 (s, 2H), 6.23 (dq, J = 10.5, 6.0 Hz, 1H), 1.92 (dd, J = 6.0, 1.1 Hz, 3H). 13 C NMR (125 MHz, DMSO) δ161.42, 154.82, 147.13, 144.39, 129.56, 126.01, 118.45, 17.04, 16.95. HRMS m / z(ESI+) C 9 H 11 N 6 + requires: 203.2210; found: 203.2208.

[0211] [ka]

[0212] The following methods can be used to dihydroxylate compound 4: 1) Sharpless asymmetric dihydroxylation reaction 5.2 g of AD-mix-α was weighed out and placed in a 250 mL three-neck flask, and 10 mL of water and 10 mL of tert-butyl alcohol were added. 2Compound 4 (143 mg) and compound 4 (120 mg) were added. The mixture was reacted at room temperature and stirred for 16 h. Insoluble matter was filtered off. The layers were separated, and the aqueous layer was extracted three times with ethyl acetate (30 mL x 3). The organic layers were combined and diluted with NaSO. 4 The crude product was dried over 1000 mg and concentrated to give 151 mg of a dark brown oil, which was then subjected to chiral synthesis to give the single chiral intermediate 2 (54 mg, 42% yield).

[0213] 2) KMnO 4 Dihydroxylation reaction by Compound 4 (100 mg) was added to THF (10 mL), the system was cooled to 0°C, pH=12, 10 mL of 1% potassium permanganate aqueous solution was added, tetrabutylammonium chloride (5 mg) was added, and the reaction was carried out at 0°C and stirred overnight. The liquids were separated, and the aqueous layer was extracted with EA (5 mL x 3), and the oil layers were combined and NaSO 4 After drying at 40° C., filtration, concentration and washing with methanol, a yellow solid was obtained, from which the chiral synthesis afforded the single chiral intermediate 2 (28 mg, 22% yield).

[0214] 3) Fe-catalyzed vicinaloxylation reaction Compound 4 (100 mg) was dissolved in THF (10 mL) and the catalyst [FeIII(L-N4Me 2 )Cl 2 ]+ 3.5mol% oxone (2 equiv) and NaHCO 3 5 mL of (6 equiv) aqueous solution was added, and the mixture was allowed to react at room temperature and stirred overnight. The liquids were separated, the oil layer was collected, concentrated, and washed with methanol to obtain the crude product as a yellow solid (76 mg). From this crude product, a single chiral intermediate 2 (16 mg, 12.4% yield) was obtained by chiral synthesis.

[0215] IR (cm -1 ) ν 3288, 1655, 1514, 1469, 1379, 1058; 1 H NMR (500 MHz, DMSO-d 6) δ 8.72 (s, 1H), 7.63 (s, 2H), 6.58 (s, 2H), 5.45 (s, 1H), 4.68 (s, 1H), 4.41 (d, J = 6.3 Hz, 1H), 3.84 (p, J = 6.2 Hz, 1H), 1.11 (d, J = 6.2 Hz, 3H); 13 C NMR (126 MHz, DMSO) δ162.93, 162.81, 155.25, 149.73, 149.60, 120.48, 76.43, 69.73, 19.55; HRMS m / z(ESI+) C 9 H 13 N 6 O 2 + requires:237.1095; found: 237.1094.

[0216] [ka]

[0217] The obtained compound 2 (54 mg) was suspended in 5 mL of aqueous NaOH (80 mg), heated to 78°C, and stirred for 3 h. The mixture was cooled to room temperature, HCOOH was added dropwise to adjust the pH to 5-6, cooled to room temperature, and the precipitated crystals were filtered to obtain compound 1, i.e., L-erythro-biopterin (51 mg, purity >99%, yield >99%); IR (cm -1 ) ν 3249, 1701, 1537, 1490, 1367, 1127; 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.42 (s, 1H), 8.70 (s, 1H), 6.87 (s, 2H), 5.58 (d, J = 4.9 Hz, 1H), 4.69 (d, J = 5.3 Hz, 1H), 4.43 (t, J = 5.3 Hz, 1H), 3.90 (h, J= 6.1 Hz, 1H), 1.05 (d, J = 6.3 Hz, 3H); 13C NMR (126 MHz, DMSO) δ 161.03, 156.55, 153.61, 151.86, 148.98, 127.08, 76.85, 69.42, 19.11. HRMS m / z (ESI+) C 9 H 12 O 3 N 5 + requires:238.0935; found: 238.0935.

[0218] Example 2 [ka]

[0219] Compound 5 (200 mg) was dispersed in 5 mL of aqueous solution containing 50 mg NaOH, heated to 78 °C, stirred for 1 h, and acetic acid was added dropwise to neutralize the system and adjust the pH to 5-6. The precipitated crystals were filtered and washed with methanol to obtain compound 5-1 (152 mg, purity 98%, yield 76%); Compound 5-1 (152 mg) was dissolved in 5 mL of a combination solution of MeOH / DCM=1 / 1, stirred thoroughly to dissolve, and Lindlar Pd (100 mg) was added. 2 (1 atm) and stirred at room temperature for 3 days. After filtering the catalyst, the solvent was concentrated to obtain compound 3 (150 mg, purity 95%, yield 93%). 1 H NMR (500 MHz, DMSO) δ 12.3 (s, 1H), 8.53 (s, 1H), 6.49 (s, 2H), 2.04 (s, 3H). 13 C NMR (125 MHz, DMSO) δ 161.85, 156.13, 150.79, 148.55, 136.37, 127.07, 92.12, 85.24, 4.59. HRMS m / z (ESI+) C 9 H 10 N 5 O + requires:203.2050, found: 203.2051

[0220] [ka]

[0221] The following methods can be used to dihydroxylate compound 3: 1) Sharpless asymmetric dihydroxylation reaction 2.6 g of AD-mix-α was weighed out and placed in a 100 mL three-neck flask, and 5 mL of HO and 5 mL of t-BuOH were added. 2 70 mg of toluene and 150 mg of compound 3 were added. The mixture was reacted at room temperature and stirred for 16 h. Insoluble matter was filtered off. The layers were separated, and the aqueous layer was extracted three times with 2-MeTHF (30 mL x 3). The organic layers were combined and diluted with NaSO 4 The crude product was dried at 40° C. and concentrated to give 56 mg of a dark brown oil, which was then subjected to chiral synthesis to give the single chiral compound 1 (19 mg, 11% yield).

[0222] 2) KMnO 4 Dihydroxylation reaction by 10 mL of 1% aqueous potassium permanganate solution (pH 12) was prepared, and 100 mg of compound 3 was added thereto. The mixture was reacted at 0° C. and stirred overnight. 2 SO 3 The reaction was quenched by adding acetic acid to adjust the pH to 5-6, the product was filtered, and the crude product was subjected to chiral synthesis to obtain single chiral compound 1 (40 mg, 21% yield).

[0223] 3) Fe-catalyzed vicinaloxylation reaction Compound 3 (150 mg) was used as a catalyst to react with [FeIII(L-N4Me 2 )Cl 2 ]+ 3.5 mol% oxone (2 equiv) and NaHCO3 (6 equiv) in water (5 mL), and the mixture was reacted at room temperature and stirred overnight. 2 SO 3The reaction was quenched by adding acetic acid, the pH was adjusted to 5-7, and the precipitated product was filtered. From this crude product, single chiral compound 1 (15 mg, yield 8.7%) was obtained by chiral synthesis.

[0224] IR (cm -1 ) ν 3249, 1701, 1537, 1490, 1367, 1127; 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.42 (s, 1H), 8.70 (s, 1H), 6.87 (s, 2H), 5.58 (d, J = 4.9 Hz, 1H), 4.69 (d, J = 5.3 Hz, 1H), 4.43 (t, J = 5.3 Hz, 1H), 3.90 (h, J= 6.1 Hz, 1H), 1.05 (d, J = 6.3 Hz, 3H); 13 C NMR (126 MHz, DMSO) δ 161.03, 156.55, 153.61, 151.86, 148.98, 127.08, 76.85, 69.42, 19.11. HRMS m / z (ESI+) C 9 H 12 O 3 N 5 + requires:238.0935; found: 238.0935.

[0225] Example 3 [ka]

[0226] Compound 8 200mg, CuI 11mg, PdCl 2 10mg,PPh 3 30 mg was weighed out and placed in a 25 mL three-neck flask, and 5 mL of acetonitrile was added. While stirring at room temperature, 0.7 mL of triethylamine and 1.1 mL of propyne (1M in THF) were added, and the mixture was allowed to react and stirred for 16 h. 10 mL of water was added to quench the reaction, and the organic layer was dried and concentrated to obtain 160 mg of crude product, which was used in the next reaction.

[0227] [ka]

[0228] 500 mg of the obtained compound 6 was placed in a high-pressure cooker, 500 mg of Lindlar catalyst and 10 mL of THF were added, and the mixture was cooled to 100° C. 2 The mixture was purged with water three times under reduced pressure and stirred at room temperature for 16 hours. The catalyst was filtered off and the mixture was concentrated to give 400 mg of compound 5a; IR (cm -1 ) ν 3401, 3202, 2222, 1644, 1492,1515, 1172; 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.27 (s, 1H), 7.33 (s, 2H), 6.30 (dq, J = 11.7, 1.8 Hz, 1H), 5.88 (dq, J = 11.7, 7.3 Hz, 1H), 2.01 (dd, J = 7.3, 1.8 Hz, 3H); 13 C NMR (126 MHz, DMSO) δ 154.87, 147.91, 141.32, 129.95, 124.29, 116.05, 109.58, 14.88; HRMS m / z (ESI+) C 8 H 9 N 4 + requires: 161.0822; found: 161.0821.

[0229] [ka]

[0230] The following methods can be used to dihydroxylate compound 5a: 1) Sharpless asymmetric dihydroxylation reaction Weigh out 6.5 g of AD-mix-α and place it in a 250 mL three-neck flask, add 10 mL of water and 10 mL of tert-butyl alcohol, and add MsNH 2180 mg of 5a and 350 mg of compound 5a were added. The mixture was reacted at room temperature and stirred for 16 h. Insoluble matter was filtered off. The layers were separated, and the aqueous layer was extracted three times with ethyl acetate (30 mL x 3). The organic layers were combined and diluted with NaSO. 4 The crude product was dried at 40° C. and concentrated to give 200 mg of a dark brown oil. The crude product was subjected to chiral synthesis to give the single chiral intermediate 4a; IR (cm -1 ) ν 3374, 3196, 2236, 1655, 1572, 1496, 1065; 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.30 (s, 1H), 7.17 (s, 2H), 5.42 (d, J = 5.1 Hz, 1H), 4.57 (d, J= 5.3 Hz, 1H), 4.21 (dd, J = 6.0, 5.1 Hz, 1H), 3.84 - 3.75 (m, 1H), 1.04 (d, J = 6.2 Hz, 3H); 13 C NMR (126 MHz, DMSO) δ 156.21, 146.77, 146.63, 116.26, 108.70, 76.21, 69.18, 19.34; HRMS m / z (ESI+) C 8 H 11 N 4 O 2 + requires: 195.0877; found: 195.0878.

[0231] 2) KMnO 4 Dihydroxylation reaction by 5-methyl-5-phenylpropanediol: Compound 5a (80 mg) was added to THF (10 mL), the system was cooled to 0°C, pH=12, 10 mL of 1% potassium permanganate aqueous solution was added, tetrabutylammonium chloride (5 mg) was added, and the reaction was carried out at 0°C and stirred overnight. The liquids were separated, and the aqueous layer was extracted with EA (5 mL x 3), and the oil layers were combined and Na 2 SO 4 After drying at 40° C., filtration, concentration, and washing with methanol, 88 mg of a yellow solid was obtained, from which the chiral synthesis afforded the single chiral intermediate 4a (31 mg, 32% yield).

[0232] 3) Fe-catalyzed vicinaloxylation reaction Compound 5a (80 mg) was dissolved in THF (10 mL) and the catalyst [FeIII(L-N4Me 2 )Cl 2 ]+ 3.5mol% oxone (2 equiv) and NaHCO 3 5 mL of an aqueous solution of (6 equiv) was added, and the mixture was allowed to react at room temperature and stirred overnight. The liquids were separated, the oil layer was collected, concentrated, and washed with methanol to obtain the crude product as a yellow solid (64 mg). From this crude product, a single chiral intermediate 4a (13 mg, 17% yield) was obtained by chiral synthesis.

[0233] [ka]

[0234] Add 62 mg of NaOH to 10 mL of MeOH and stir until complete reaction, then add 226 mg of guanidinium hydrochloride and add N 2 The mixture was stirred for 5 min under room temperature. The insoluble matter in the system was filtered, and 200 mg of single chiral intermediate 4a was added. The mixture was heated to reflux and stirred for 18 h. The reaction system was cooled to room temperature and stirred for 1 h. The yellow crystals precipitated in the system were filtered to obtain 150 mg of compound 2 (purity >99%, yield 68%).

[0235] [ka]

[0236] The obtained compound 2 (100 mg) was suspended in 10 mL of NaOH (160 mg) aqueous solution, heated to 78°C, and stirred for 3 h. The mixture was cooled to room temperature, HCOOH was added dropwise to adjust the pH to 5-6, cooled to room temperature, and the precipitated crystals were filtered to obtain compound 1, i.e., L-erythro-biopterin (100 mg, purity >99%, yield >99%); IR (cm -1 ) ν 3249, 1701, 1537, 1490, 1367, 1127; 1H NMR (500 MHz, DMSO-d 6 ) δ 11.42 (s, 1H), 8.70 (s, 1H), 6.87 (s, 2H), 5.58 (d, J = 4.9 Hz, 1H), 4.69 (d, J = 5.3 Hz, 1H), 4.43 (t, J = 5.3 Hz, 1H), 3.90 (h, J= 6.1 Hz, 1H), 1.05 (d, J = 6.3 Hz, 3H); 13 C NMR (126 MHz, DMSO) δ 161.03, 156.55, 153.61, 151.86, 148.98, 127.08, 76.85, 69.42, 19.11. HRMS m / z (ESI+) C 9 H 12 O 3 N 5 + requires:238.0935; found: 238.0935.

[0237] Example 4 [ka]

[0238] Compound 8 200 mg, E-phenylboronic acid 104 mg, Pd(dppf)Cl 2 37mg, K 2 CO 3 Weigh out 500mg of 1,4-diox / H 2 The mixture was dissolved in O (v / v=3 mL / 2 mL), reacted, heated to reflux, and stirred for 3 h. TLC analysis confirmed that the reaction was complete. The mixture was separated, and the aqueous layer was extracted with EA and the oil layer was combined with Na 2 SO 4 The mixture was dried at 40° C., concentrated and subjected to column chromatography to give a yellow solid 5b (100 mg); IR (cm -1 ) ν 3384, 2231, 1667, 1574, 1498, 1316, 1166; 1 H NMR (500 MHz, DMSO-d 6) δ 8.31 (s, 1H), 7.18 (s, 2H), 5.35 (d, J = 5.4 Hz, 1H), 4.54 (d, J = 5.4 Hz, 1H), 4.26 (t, J = 5.0 Hz, 1H), 3.81 - 3.71 (m, 1H), 1.00 (d, J = 6.4 Hz, 3H); 13 C NMR (126 MHz, DMSO) δ 156.14, 146.56, 146.40, 116.20, 108.75, 75.85, 69.04, 19.22; HRMS m / z (ESI+) C 8 H 11 N 4 O 2 + requires: 195.0879; found: 195.0877.

[0239] [ka]

[0240] The following methods can be used to dihydroxylate compound 5b: 1) Sharpless asymmetric dihydroxylation reaction Weigh out 7.0 g of AD-mix-α and dissolve it in t-BuOH / H 2 2H2O (30 mL / 30 mL), stirred at 0 °C for 5 min, and then added MsNH 2 Add 475mg of compound 5b, stir at 0℃ for 5min, add 800mg of compound 5b, raise the temperature to 4℃ and stir for 2d, check whether the reaction is complete by HPLC, and add Na 2 SO 3 Add 10g of EA to the system, stir at room temperature for 30 min, filter, wash the filter residue with 50mL of EA, separate the filtrate, extract the aqueous layer with 5mL of EA x 3, combine the organic layers, and add Na 2 SO 4 The mixture was dried at 40° C. and purified by column chromatography (HEP:EA=5:1-0:1) to give a pale yellow solid 4b (1.08 g, yield >99%, purity=98% ee=94%); IR (cm -1) ν 3384, 2231, 1667, 1574, 1498, 1316, 1166; 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.31 (s, 1H), 7.18 (s, 2H), 5.35 (d, J = 5.4 Hz, 1H), 4.54 (d, J= 5.4 Hz, 1H), 4.26 (t, J = 5.0 Hz, 1H), 3.81 - 3.71 (m, 1H), 1.00 (d, J = 6.4 Hz, 3H); 13 C NMR (126 MHz, DMSO) δ 156.14, 146.56, 146.40, 116.20, 108.75, 75.85, 69.04, 19.22; HRMS m / z (ESI+) C 8 H 11 N 4 O 2 + requires: 195.0879; found: 195.0877.

[0241] 2) KMnO 4 Dihydroxylation reaction by Compound 5b (80 mg) was added to THF (10 mL), the system was cooled to 0°C, pH=12 1% potassium permanganate aqueous solution (10 mL) was added, tetrabutylammonium chloride (5 mg) was added, and the mixture was reacted at 0°C and stirred overnight. The mixture was separated, the aqueous layer was extracted with EA (5 mL x 3), the oil layer was combined, dried over Na2SO4, filtered, concentrated, and washed with methanol to obtain a yellow solid (91 mg). From this crude product, a single chiral intermediate 4b (33 mg, 34% yield) was obtained by chiral synthesis.

[0242] 3) Fe-catalyzed vicinaloxylation reaction Compound 5b (80 mg) was dissolved in THF (10 mL) and the mixture was stirred with [FeIII(L-N4Me 2 )Cl 2]+ 3.5mol% oxone (2 equiv) and NaHCO3 (6 equiv) aqueous solution (5 mL) was added and reacted at room temperature and stirred overnight. The mixture was separated, the oil layer was collected, concentrated, and washed with methanol to obtain the crude product as a yellow solid (64 mg). From this crude product, single chiral intermediate 4b (15 mg, 20% yield) was obtained by chiral synthesis.

[0243] IR (cm -1 ) ν 3384, 2231, 1667, 1574, 1498, 1316, 1166; 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.31 (s, 1H), 7.18 (s, 2H), 5.35 (d, J = 5.4 Hz, 1H), 4.54 (d, J = 5.4 Hz, 1H), 4.26 (t, J = 5.0 Hz, 1H), 3.81 - 3.71 (m, 1H), 1.00 (d, J = 6.4 Hz, 3H); 13 C NMR (126 MHz, DMSO) δ 156.14, 146.56, 146.40, 116.20, 108.75, 75.85, 69.04, 19.22; HRMS m / z(ESI+) C 8 H 11 N 4 O 2 + requires: 195.0879; found: 195.0877.

[0244] [ka]

[0245] Disperse 800 mg of compound 4b in 100 mL of ACN, stir thoroughly, and add H 3 CC(OEt) 3 Add 1.48g of PTSA and 39mg of PTSA, stir until completely dissolved, and continue stirring for 30min. 2Add 1mL of O to the system and continue to stir for 30min. Check by TLC whether the raw materials are completely reacted. Two products are generated. Directly add silica gel to the system. After stirring the sample, 400mg of compound 3b-2 and 421mg of a mixture of compound 3b-1 and compound 3b-2 are obtained by column chromatography. The mixture of compound 3b-1 and compound 3b-2 is separated by NH 3 / MeOH solution and stirred for 30 min to produce compound 4b. The above monoacetylation reaction was repeated to obtain 260 mg of compound 3b-2. The compound 3b-2 obtained by the two reactions was 660 mg, with a purity of 90% and a yield of 61%;

[0246] Spectrogram data of compound 3b-2: IR (cm -1 ) ν 3452, 3340, 2223, 1697, 1616, 1482, 1372,1044; 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.33 (s, 1H), 7.29 (s, 2H), 5.77 (d, J = 5.3 Hz, 1H), 5.03 (qd, J= 6.5, 5.1 Hz, 1H), 4.53 (t, J = 5.3 Hz, 1H), 1.93 (s, 3H), 1.10 (d, J= 6.5 Hz, 3H). 13 C NMR (126 MHz, DMSO) δ 169.75, 156.23, 146.23, 144.84, 115.98, 109.15, 73.02, 72.05, 20.88, 16.00. HRMS m / z (ESI+) C 10 H 12 O 3 N 4 Na + requires:259.0802; found: 259.0801.

[0247] [ka]

[0248] Compound 3b - 2500 mg, naproxen 732 mg, PPh 3 834mg was weighed and dissolved in 30mL of THF, and 0.63mL of DIAD was added dropwise at 0℃ to react and stir overnight. The reaction was confirmed to be complete by HPLC, and the system was quenched by adding saturated aqueous NaHCO3 solution, separated, and the aqueous layer was extracted with 20mLx2 of EA. The oil layers were combined and Na 2 SO 4 The resulting mixture was dried over 500 ml of ethyl acetate, concentrated, and purified by column chromatography (EA / Heptane=1 / 2) to give compound 2b-1 (272 mg, purity 97%, yield 28%). 3 / MeOH solution and stirred for 1 h to produce 260 mg of compound 4b again, which was recovered as the raw material for the upstream reaction.

[0249] Spectrogram data of compound 2b-1: IR (cm -1 ) ν 3331, 2224, 1740, 1630, 1233 1 H NMR (500 MHz, DMSO-d 6 ) δ 7.90-7.69 (m, 4H), 7.48-7.36 (m, 3H), 7.34 - 7.23 (m, 1H), 7.19 - 7.10 (m, 1H), 5.69 (d, J = 4.2 Hz, 1H), 5.28 -5.13 (m, 1H), 4.05 (q, J = 7.0 Hz, 1H), 3.86 (s, 3H), 1.89 (s, 3H), 1.51 (d, J = 7.1 Hz, 3H), 1.09 (d, J = 6.6 Hz, 3H); 13C NMR (126 MHz, DMSO) δ 172.77, 169.44, 157.23, 156.29, 145.61, 139.20, 134.99, 133.36, 129.14, 128.36, 126.92, 126.27, 125.81, 118.82, 115.55, 109.62, 105.74, 74.45, 69.72, 55.15, 44.36, 20.64, 17.80, 14.74. 24 H 24 O 5 N 4 Na + requires:471.1639; found:471.1637.

[0250] [ka]

[0251] Weighed out 77 mg of Na, added it to 30 mL of methanol, and thoroughly stirred until it reacted completely. To the resulting 3 mL, add 32 mg of guanidinium hydrochloride, and 2 After stirring for 5 min under protection and filtering insoluble matters, 50 mg of compound 2b-1 was added and reacted, heated to reflux and stirred overnight to precipitate bright yellow crystals. The precipitated crystals were filtered to obtain compound 2 (15.3 mg, yield 58%); IR (cm -1 ) ν 3288, 1655, 1514, 1469, 1379, 1058; 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.72 (s, 1H), 7.63 (s, 2H), 6.58 (s, 2H), 5.45 (s, 1H), 4.68 (s, 1H), 4.41 (d, J= 6.3 Hz, 1H), 3.84 (p, J = 6.2 Hz, 1H), 1.11 (d, J = 6.2 Hz, 3H); 13C NMR (126 MHz, DMSO) δ 162.93, 162.81, 155.25, 149.73, 149.60, 120.48, 76.43, 69.73, 19.55; HRMS m / z (ESI+) C 9 H 13 N 6 O 2 + requires:237.1095; found: 237.1094.

[0252] [ka]

[0253] The obtained compound 2 (100 mg) was suspended in 10 mL of aqueous NaOH (160 mg), heated to 78° C., and stirred for 3 h. The mixture was cooled to room temperature, HCOOH was added dropwise, pH was adjusted to 5-6, and the mixture was cooled to room temperature. The precipitated crystals were filtered to obtain compound 1, i.e., L-erythro-biopterin (100 mg, purity >99%, yield >99%).

[0254] Example 5 [ka]

[0255] The following methods can be used to dihydroxylate compound 5b: 1) Sharpless asymmetric dihydroxylation reaction Weigh out 7.0 g of AD-mix-β and dissolve it in t-BuOH / H 2 2H2O (30 mL / 30 mL), stirred at 0 °C for 5 min, and then added MsNH 2 Add 475mg of compound 5b, stir at 0℃ for 5min, add 800mg of compound 5b, raise the temperature to 4℃ and stir for 2d, check whether the reaction is complete by HPLC, and add Na 2 SO 3Add 10g of EA to the system, stir at room temperature for 30 min, filter, wash the filter residue with 50mL of EA, separate the filtrate, extract the aqueous layer with 5mL of EA x 3, combine the organic layers, and add Na 2 SO 4 The mixture was dried at rt and purified by column chromatography to give a pale yellow solid 4b-1 (979 mg, yield >99%, purity = 98%, ee = 92%) (HEP:EA = 5:1-0:1).

[0256] IR (cm -1 ) ν 3374, 2230, 1668, 1570, 1486, 1166; 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.31 (s, 1H), 7.18 (s, 2H), 5.35 (d, J = 5.4 Hz, 1H), 4.54 (d, J = 5.4 Hz, 1H), 4.26 (t, J = 5.0 Hz, 1H), 3.81 - 3.71 (m, 1H), 1.00 (d, J = 6.4 Hz, 3H); 13 C NMR (126 MHz, DMSO) δ 156.14, 146.56, 146.40, 116.20, 108.75, 75.85, 69.04, 19.22; HRMS m / z (ESI+) C 8 H 11 N 4 O 2 + requires: 195.0879; found: 195.0877.

[0257] 2) KMnO 4 Dihydroxylation reaction by Compound 5b (80 mg) was added to THF (10 mL), the system was cooled to 0°C, pH=12, 10 mL of 1% potassium permanganate aqueous solution was added, tetrabutylammonium chloride (5 mg) was added, and the reaction was carried out at 0°C and stirred overnight. The liquids were separated, and the aqueous layer was extracted with EA (5 mL x 3), and the oil layers were combined and Na 2 SO 4After drying at 40° C., filtration, concentration, and washing with methanol, 91 mg of a yellow solid was obtained, from which the chiral synthesis afforded the single chiral intermediate 4b-1 (29 mg, 30% yield).

[0258] 3) Fe-catalyzed vicinaloxylation reaction Compound 5b (80 mg) was dissolved in THF (10 mL) and the mixture was stirred with [FeIII(L-N4Me 2 )Cl 2 ]+ 3.5 mol% oxone (2 equiv) and NaHCO3 (6 equiv) aqueous solution (5 mL) were added, and the mixture was reacted at room temperature and stirred overnight. The mixture was separated, the oil layer was collected, concentrated, and washed with methanol to obtain the crude product as a yellow solid (64 mg). From this crude product, chiral synthesis was performed to obtain a single chiral intermediate 4b-1 (12 mg, 16% yield); IR (cm -1 ) ν 3384, 2231, 1667, 1574, 1498, 1316, 1166; 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.31 (s, 1H), 7.18 (s, 2H), 5.35 (d, J = 5.4 Hz, 1H), 4.54 (d, J= 5.4 Hz, 1H), 4.26 (t, J = 5.0 Hz, 1H), 3.81 - 3.71 (m, 1H), 1.00 (d, J = 6.4 Hz, 3H); 13 C NMR (126 MHz, DMSO) δ 156.14, 146.56, 146.40, 116.20, 108.75, 75.85, 69.04, 19.22; HRMS m / z (ESI+) C 8 H 11 N 4 O 2 + requires: 195.0879; found: 195.0877.

[0259] [ka]

[0260] Compound 4b-1, 800 mg, was dispersed in 100 mL of ACN, stirred thoroughly, and then diluted with H 3 CC(OEt) 3 Add 1.48g of PTSA and 39mg of PTSA, stir until completely dissolved, continue stirring for 30min, and then add 1.48g of PTSA and 39mg of PTSA. 2 Add 1mL of O to the system and continue to stir for 30min. Check whether the raw materials are completely reacted by TLC. Two products are generated. Add silica gel directly to the system. After stirring the sample, obtain 200mg of compound 3b-3 and 611mg of a mixture of compound 3b-4 and compound 3b-3 by column chromatography. The mixture of compound 3b-4 and compound 3b-3 is separated with NH 3 / MeOH solution and stirred for 30 min to produce compound 4b-1. The above monoacetylation reaction was repeated to obtain 240 mg of compound 3b-3. The compound 3b-4 obtained by two reactions was a total of 440 mg, with a purity of 90% and a yield of 41%; IR (cm -1 ) ν 3426, 2220, 1683, 1606, 1485, 1373; 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.28 (s, 1H), 7.38 (s, 2H), 5.38 (d, J = 6.0 Hz, 1H), 4.04-3.96 (m, 1H), 2.08 (s, 3H), 0.98 (d, J = 6.4 Hz, 3H); 13 C NMR (126 MHz, DMSO) δ 170.00, 156.37, 146.69, 141.44, 115.84, 109.67, 77.50, 66.91, 20.81, 19.06. HRMS m / z (ESI+) C 10 H 12 O 3 N 4 Na + requires:259.0802; found: 259.0803.

[0261] [ka]

[0262] Compound 3b-3 100 mg, naproxen 147 mg, PPh 3 167 mg of the product was weighed out and dissolved in 10 mL of THF, and 0.2 mL of DIAD was added dropwise at 0°C to react and stir overnight. The reaction was confirmed to be complete by HPLC, and the system was then saturated with NaHCO 3 The mixture was quenched with aqueous solution, separated, and the aqueous layer was extracted with EA (20 mL x 2). 2 SO 4 The mixture was dried at 40° C., concentrated, and purified by column chromatography (EA / Heptane=1 / 2) to give compound 2b-3 (52 mg, purity 97%, yield 27%).

[0263] [ka]

[0264] Weighed out 77 mg of Na, added it to 30 mL of methanol, and thoroughly stirred until it reacted completely. To the resulting 3 mL, add 32 mg of guanidinium hydrochloride, and 2 After stirring for 5 min under protection and filtering insoluble matters, 50 mg of compound 2b-3 was added and reacted, heated to reflux and stirred overnight to precipitate bright yellow crystals. The precipitated crystals were filtered to obtain compound 2 (16.8 mg, 64% yield); IR (cm -1 ) ν 3329, 2222, 1736, 1625, 1225 1 H NMR (500 MHz, DMSO-d 6 ) δ 7.99-7.65 (m, 4H), 7.51-7.36 (m, 3H), 7.34 -7.21 (m, 1H), 7.20 -7.08 (m, 1H), 5.58 (d, J = 4.2 Hz, 1H), 5.31 - 5.10 (m, 1H), 4.09 (q, J = 7.0 Hz, 1H), 3.74 (s, 3H), 1.56 (s, 3H), 1.49 (d, J = 7.1 Hz, 3H), 1.10 (d, J = 6.6 Hz, 3H); 13C NMR (126 MHz, DMSO) δ 174.53, 167.36, 157.37, 156.89, 148.58, 138.26, 134.93, 130.35, 129.54, 127.87, 126.92, 126.27, 123.21, 117.72, 112.51, 106.42, 103.14, 73.25, 66.71, 55.36, 47.63, 21.64, 19.83, 12.79. 24 H 24 O 5 N 4 Na + requires:471.1639; found:471.1638.

[0265] [ka]

[0266] 100 mg of the obtained compound 2 was suspended in 10 mL of an aqueous solution of NaOH (160 mg), heated to 78°C to react, and stirred for 3 h. The mixture was cooled to room temperature, HCOOH was added dropwise, pH was adjusted to 5-6, and the mixture was cooled to room temperature. The precipitated crystals were filtered to obtain compound 1, i.e., L-erythro-biopterin (100 mg, purity >99%, yield >99%).

[0267] Example 6 [ka]

[0268] Compound 8 10g (50mmol), CuI 475mg (2.5mmol), PdCl 2 (440mg 2.5mmol), TPP 1.3g (5mmol), TEA (25.3g 250mmol) and propyne 55mL (1M) were dissolved in acetonitrile 250mL, reacted and stirred at room temperature for 16h. After checking by HPLC whether the raw materials were completely converted to the product, H 2Wash with 100 mL of O, separate the layers, extract the aqueous layer with 25 mL of EA x 3, collect the oil layer, and add Na 2 SO 4 The mixture was dried at 40° C. and purified by column chromatography (EA:Heptane=3:1) to obtain 7.8 g of compound 6 as yellow crystals in a yield of 98.7%.

[0269] [ka]

[0270] Compound 6 (2 g, 12.5 mmol) was placed in a hydrogenation reactor, 20 mL of 2-MeTHF was added, and the mixture was dissolved. Lindlar Pd (20 mg) was added. 2 The mixture was purged under reduced pressure, pressurized to 0.2 MPa, stirred at room temperature, and confirmed by HPLC that the reaction proceeded until the raw material just disappeared. The Lindlar Pd was filtered, concentrated, and purified by column chromatography (EA:Heptane=1:3) to obtain 1.9 g of compound 5a as yellow crystals. IR (cm -1 ) ν 3401, 3202, 2222, 1644, 1492,1515, 1172; 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.27 (s, 1H), 7.33 (s, 2H), 6.30 (dq, J = 11.7, 1.8 Hz, 1H), 5.88 (dq, J= 11.7, 7.3 Hz, 1H), 2.01 (dd, J = 7.3, 1.8 Hz, 3H); 13 C NMR (126 MHz, DMSO) δ 154.87, 147.91, 141.32, 129.95, 124.29, 116.05, 109.58, 14.88; HRMS m / z (ESI+) C 8 H 9 N 4 + requires: 161.0822; found: 161.0821.

[0271] [ka]

[0272] K 2 OsO 4 2H 2 O 1.5mg (4 μmol), DHQ-IND 20mg (40 μmol), K 2 CO 3 840mg (6mmol), K 3 [Fe(CN) 6 ] 2g (6 mmol) of H 2 Dissolve in 0 / t-BuOH (10mL / 10mL), stir at room temperature until completely dissolved, add compound 5a, react, stir at room temperature overnight (about 18h), check whether the reaction is complete by HPLC, separate, collect the oil layer, extract the aqueous layer with 2-MeTHF until no residue remains, and add Na 2 SO 4 The mixture was dried at 47° C., filtered, concentrated and subjected to column chromatography to obtain 110 mg of a mixture of 4a and 4b (er=62:38) as white crystals.

[0273] [ka]

[0274] The mixture of 4a and 4b (220 mg, er = 62:38) obtained above was dispersed in 5 mL of toluene, heated to reflux, 225 mg of boric acid isopropyl ester was added, the solvent in the system was removed, and the mixture was refluxed for 30 min. 121 mg of prolinol was added, and the mixture was refluxed for 30 min. The mixture was then cooled to room temperature, and the precipitated solid was filtered. The filter cake was thoroughly washed with 2-MeTHF, and the filter cake was collected to obtain compound 3a as white crystals (144 mg), with a yield of 42%, chemical purity of 99%, and diastereomeric ratio (dr) 3a:3b = 96:4.

[0275] [ka]

[0276] Compound 3a (dr=99:1) (1 g) was dispersed in 2-MeTHF (10 mL) and saturated K 2 CO 3 Add 5mL of 2-MeTHF, stir until completely dissolved, separate the layers, extract the aqueous layer with 10mL x 3 2-MeTHF, combine the organic layers, and add Na 2 SO 4 The extract was dried over 750 ml of ethyl acetate, filtered, concentrated and purified by column chromatography (EA:Heptane=1:3) to give 620 mg (purity 99%, 98% ee) of compound 4a as white crystals.

[0277] [ka]

[0278] 638 mg (7.3 mmol) of guanidinium hydrochloride was dissolved in 7 mL of methanol, 1.4 mL of sodium methylate (5 M in MeOH) was added, and the mixture was stirred for 10 min. The precipitated solid was filtered, the filtrate was collected, and 320 mg of compound 4a (1.67 mmol, >99% ee) was added and the mixture was heated under reflux overnight. After cooling to room temperature, the mixture was filtered and the filter cake was collected to obtain 250 mg (>99.9% ee, purity 99%, yield 64%) of compound 2 as yellow crystals.

[0279] [ka]

[0280] 638 mg (7.3 mmol) of guanidinium hydrochloride was dissolved in 7 mL of methanol, 1.4 mL of sodium methylate (5 M in MeOH) was added, and the mixture was stirred for 10 min. The precipitated solid was filtered, the filtrate was collected, and 500 mg of 3a (1.65 mmol, 3a:3b = 94:6) was added, and the mixture was heated under reflux overnight. After cooling to room temperature, the mixture was filtered, and the filter cake was collected to obtain 244 mg (>99.9% ee, purity 99%, yield 63%) of compound 2 as yellow crystals.

[0281] IR (cm -1) ν 3249, 1701, 1537, 1490, 1367, 1127; 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.42 (s, 1H), 8.70 (s, 1H), 6.87 (s, 2H), 5.58 (d, J = 4.9 Hz, 1H), 4.69 (d, J = 5.3 Hz, 1H), 4.43 (t, J = 5.3 Hz, 1H), 3.90 (h, J = 6.1 Hz, 1H), 1.05 (d, J= 6.3 Hz, 3H); 13 C NMR (126 MHz, DMSO) δ 161.03, 156.55, 153.61, 151.86, 148.98, 127.08, 76.85, 69.42, 19.11. HRMS m / z (ESI+) C 9 H 12 O 3 N 5 + requires:238.0935; found: 238.0935.

[0282] [ka]

[0283] Compound 2 (89 mg, purity 99%, 99.9% ee) was dispersed in 5 mL of NaOH (15 mg) aqueous solution, heated to 50°C, and stirred for 4 h. When the conversion rate of the reaction confirmed by HPLC reached about 90%, 100 mg of NaOH was added, the temperature was raised to 78°C, and after the reaction was completed, 10 mg of activated carbon was added, decolorized, filtered, and washed with 1 mL of n-butanol, separated, the aqueous layer was collected, and neutralized to pH = 7 with 1 M diluted hydrochloric acid to obtain compound 1 as a white solid (78 mg), yield 87%, chemical purity 99%, 99.9% ee. IR (cm -1 ) ν 3249, 1701, 1537, 1490, 1367, 1127; 1 H NMR (500 MHz, DMSO-d 6) δ 11.42 (s, 1H), 8.70 (s, 1H), 6.87 (s, 2H), 5.58 (d, J = 4.9 Hz, 1H), 4.69 (d, J = 5.3 Hz, 1H), 4.43 (t, J = 5.3 Hz, 1H), 3.90 (h, J = 6.1 Hz, 1H), 1.05 (d, J= 6.3 Hz, 3H); 13 C NMR (126 MHz, DMSO) δ 161.03, 156.55, 153.61, 151.86, 148.98, 127.08, 76.85, 69.42, 19.11. HRMS m / z (ESI+) C 9 H 12 O 3 N 5 + requires:238.0935; found: 238.0935.

[0284] Example 7 The preparation method of the racemic mixture of 4a and 4b is the same as in Example 1; [ka]

[0285] 100mg of the racemic mixture of 4a and 4b was dissolved in 5mL of acetonitrile, and 117mg of boric acid isopropyl ester was added at the same time, and the mixture was refluxed and stirred for 30min. 93.4mg of L-phenylalaninol was dissolved in acetonitrile, and the solution was added to the reaction system. The mixture was refluxed for about 15min, and precipitation occurred. The precipitate was filtered, and product 9a was obtained as white crystals (72mg), with a chemical purity of 99% and a diastereomeric ratio (dr) of 9a:9b =99.2:0.8.

[0286] Structural Verification Test After partitioning of L-prolinol, the products (compound 3a, [ka] ) XRD data was obtained for the production of The measuring device was a D8 Ventur, and the device parameters were as shown in Table 1 below.

[0287] [Table 2]

[0288] Structure analysis and refinement process: After the integration and restoration of the diffraction data using the SAINT program, the data were empirically corrected using the SADABS program; the single crystal structure was solved by direct methods using SHELXT2014, the structure was refined by the least-squares method, and the refinement process of hydrogen atoms was obtained by isotropic calculation processing, and the hydrogen atoms of CH were calculated by hydrogen loading and refined by the riding model.

[0289] Diffraction intensity data was collected using a D8 Venture X-ray diffractometer with a Cu target (Cu-Kα (=1.54018 Å)), graphite monochromator, single tube diameter Φ = 0.50 mm, distance between crystal and CMOS detector d = 40 mm, resolution: 0.80 Å, tube voltage 50 KV, tube current 1.2 mA, scan mode: Φ and ω scan, total number of collected diffraction points 6738, number of independent diffraction points 2751, number of observable points (

number

[0290] [Table 3]

[0291] [Table 4]

[0292] [Table 5]

[0293] [Table 6]

[0294] [Table 7]

[0295] [Table 8] TIFF0007587862000142.tif135170

[0296] Although each technical feature of the above embodiments can be implemented in any combination, for the sake of brevity, not all possible combinations of each technical feature in the above embodiments will be described; however, as long as there is no contradiction in the combination of these technical features, it should be understood that it is within the scope of the description of this specification.

[0297] The above examples only represent some embodiments of the present invention, and the description is more specific and detailed, but it should not be understood as being limited to the scope of the present invention. It should be pointed out that for those with ordinary skill in the art, some modifications and improvements can be made without departing from the concept of the present invention, and all of these are within the protection scope of the present invention. Therefore, the protection scope of this patent shall be subject to the scope of the attached claims.

Claims

1. An intermediate having a structure represented by formula (IVa-1) or formula (IVa-2): 【Chemistry 1】 During the ceremony, 【Chemistry 2】 has the following structure: 【Chemistry 3】 【Chemistry 4】 has the following structure: 【Chemistry 5】 W is NH x where X is 0, 1 or 2; R 1 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocycloalkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group; R 2 and R 3 are each independently a hydrogen atom or a protecting group for an amino group, R 2 and R 3 is the above R 2 and R 3 can form a cyclic lactim group together with the nitrogen atom bonded to the amino protecting group is selected from -Boc, -Cbz, -Ac, -Ts, -Ms, -Bz, -Bn, -PMB, or a Schiff base; R 4 -COOR 5 , -CONHR 6 or -CN; R 5 and R 6 each independently represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocycloalkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group; Z is a hydrogen atom or a leaving group; The leaving group is a halogen, OSOnR 9 , O.C.O.R. 10 or OPO 2 R 11 where R 9 , R 10 or R 11 are independently -CF 3 , alkyl, phenyl or alkyl-substituted phenyl, where n is 0, 1 or 2; Y is O or absent.

2. The Y is absent, Z is a hydrogen atom, R 4 is a cyano group, R 1 2. The intermediate according to claim 1, wherein: is a methyl group.

3. The manufacturing method includes the steps of: A method for producing an intermediate according to any one of claims 1 to 2, comprising mixing a compound to be resolved, a first reagent, a second reagent, and an aprotic solvent, heating under reflux, and after completion of the reaction, crystallizing to obtain an intermediate having a structure represented by formula (IVa-1) or formula (IVa-2); wherein the compound to be resolved is a mixture of formula (IVa) and formula (IVa'), the first reagent is a borate ester or boric acid, and the second reagent is a chiral amino alcohol. 【Chemistry 6】

4. The method according to claim 3, characterized in that the compound to be resolved is reacted with the first reagent to produce a mixture of structures represented by formula (IVa-3) and formula (IVa-4); and the mixture of structures represented by formula (IVa-3) and formula (IVa-4) is reacted with the second reagent to obtain an intermediate of a structure represented by formula (IVa-1) or formula (IVa-2).

5. The aprotic solvent is selected from one or more of tetrahydrofuran and 2-methyltetrahydrofuran, cyclopentyl methyl ether, acetonitrile, toluene, benzene, dimethylbenzene, 1,4-dioxane, acetone, MIBK; and the molar ratio of the compound to be resolved to the second reagent is less than or equal to 1; and The molar ratio of the first reagent to the second reagent is 1:(1.0-1.3); and The method according to claim 3, characterized in that 1-100 mL of the aprotic solvent is added per gram of the compound to be resolved.

6. The intermediate according to any one of claims 1 to 2, for producing an L-erythro-biopterin compound.

7. An L-erythro-biopterin compound has a structure represented by formula (I), and the L-erythro-biopterin compound represented by (I) is produced from a compound represented by formula (II) or a compound represented by formula (III) by a dihydroxylation reaction; 【Chemistry 7】 During the ceremony, Y is O or absent; Z is a hydrogen atom or a leaving group; R 1 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocycloalkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group; R 2 and R 3 are each independently a hydrogen atom or a protecting group for an amino group, R 2 and R 3 is the above R 2 and R 3 can form a cyclic lactam group together with the nitrogen atom to which it is bonded; R 4 -COOR 5 , -CONHR 6 or -CN; R 5 and R 6 each independently represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocycloalkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group; R 7 -OH or -NH 2 is; When the alkene in the compound represented by formula (II) has a cis structure and its structural formula is represented by formula (IIa), the procedure for preparing the L-erythrobiopterin compound represented by formula (I) from the compound represented by formula (IIa) is as follows: The compound of formula (IIa) undergoes a dihydroxylation reaction to obtain compounds to be separated, which are composed of compounds of formula (IVa) and formula (IVa'); The compound to be separated is resolved with a chiral resolving agent to obtain a compound represented by formula (IVa-1); The compound represented by formula (IVa-1) is 【Chemistry 8】 and / or 【Chemistry 9】 and then carrying out a hydrolysis reaction to obtain an L-erythrobiopterin compound represented by formula (I). Wherein, the chiral resolution reagent set includes a first reagent and a second reagent, the first reagent being a borate ester or boric acid; The second reagent is a chiral amino alcohol; 【Chemistry 10】 , W, Z, Y, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 is as defined in claim 1; E is halogen, C 1-4 Alkoxy, C1-4 Alkylsulfanyl or -NH 2 is; 【Chemistry 11】 When the alkene in the compound represented by formula (II) is a trans structure and the structural formula thereof is represented by formula (IIb), the procedure for preparing the L-erythrobiopterin compound represented by formula (I) from the compound represented by formula (IIb) is as follows: The compound represented by formula (IIb) is subjected to a dihydroxylation reaction to prepare a compound represented by formula (IVb-1) and / or formula (IVb-2); The compound represented by formula (IVb-1) and / or formula (IVb-2) undergoes an acetylation reaction to obtain a compound represented by formula (VIIb-1) and / or formula (VIIb-2); The compounds represented by formula (VIIb-1) and / or formula (VIIb-2) undergo a Mitsunobu reaction to give compounds represented by formula (VIIb-3) and / or formula (VIIb-4); The compounds represented by formula (VIIb-3) and / or formula (VIIb-4) are 【Chemistry 12】 and / or 【Chemistry 13】 to obtain an L-erythrobiopterin compound represented by formula (I). 【Chemistry 14】 Here, R 10 is substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; E is halogen, C 1-4 Alkoxy, C 1-4 A method for producing an L-erythro-biopterin compound, which is characterized in that the compound is alkylthio or -NH2.

8. R 5 and R 6 each independently represents a hydrogen atom or a substituted or unsubstituted C 1-20 selected from alkyl groups; R 1 is C 1-6 an alkyl group, a 3- to 8-membered cycloalkyl group, a 3- to 10-membered aryl group, a 3- to 10-membered heteroaryl group, or -CH 2 The method for producing an L-erythro-biopterin compound according to claim 7, characterized in that X is selected from the group consisting of 1 and 2; X is a leaving group.

9. The leaving group is a halogen, OSO n R 9 , O.C.O.R. 10 Or OPO 2 R 11 where R 9 , R 10 or R 11 are each independently -CF 3 , an alkyl group, a phenyl group, or a phenyl group substituted with an alkyl group, and n is 0, 1, or 2; and / or The method for producing an L-erythro-biopterin compound according to claim 8, wherein the protecting group for the amino group is selected from -Boc, -Cbz, -Ac, -Ts, -Ms, -Bz, -Bn, -PMB, or a Schiff base.

10. The Y is absent, Z is a hydrogen atom, R is a cyano group, R 1 The method for producing an L-erythrobiopterin compound according to claim 9, characterized in that is a methyl group.

11. The process for obtaining the compound represented by formula (IVa-1) also includes the steps of: Mixing the compound represented by formula (IVa-1) with a protic solvent to obtain a compound represented by formula (IVa); A compound represented by formula (IVa) 【Chemistry 15】 and / or 【Chemistry 16】 The method for producing an L-erythro-biopterin compound according to claim 7, characterized in that the salt is reacted in the order of cyclization and hydrolysis to obtain an L-erythro-biopterin compound represented by formula (I). 【Chemistry 17】

12. A compound represented by formula (IVa-1), 【Chemistry 18】 and / or 【Chemistry 19】 The process for the salt to undergo cyclization followed by hydrolysis includes the following steps: A compound represented by formula (IVa-1), 【Chemistry 20】 and / or 【Chemistry 21】 Mix salt, alkali and protic solvent, heat to 50-100°C, cool after the reaction is completed, and precipitate solid is filtered to obtain the compound represented by formula (I-1); The compound represented by formula (I-1) is added to an alkaline solution, and after the reaction is completed, an acid is added to adjust the pH to 5 to 6. The precipitated crystals are filtered and dried to obtain an L-erythro-biopterin compound represented by formula (I); 【Chemistry 22】 R 7 -OH or -NH 2 The method for producing an L-erythrobiopterin compound according to claim 7, characterized in that

13. The borate ester is selected from trimethyl borate, triethyl borate, triisopropyl borate, or pinacol isopropoxyboronate; The method for producing an L-erythro-biopterin compound according to claim 7, characterized in that the chiral amino alcohol is selected from L-phenylglycinol, L-prolinol, L-phenylalaninol, (S)-α,α-diphenylprolinol, or quinine.

14. The method for producing an L-erythro-biopterin compound according to any one of claims 7 to 13, characterized in that the dihydroxylation reaction is performed by a Sharpless asymmetric dihydroxylation reaction, a basic KMnO4 dihydroxylation reaction, an Fe-catalyzed vicinal oxylation reaction, or an asymmetric epoxidation followed by a ring-opening reaction by hydrolysis.

15. The compound represented by formula (IIa) and / or the compound represented by formula (IIb) are dihydroxylated by a Sharpless asymmetric dihydroxylation reaction, and the Sharpless asymmetric dihydroxylation reaction process includes the following steps: The compound represented by formula (IIa) and / or the compound represented by formula (IIb) is mixed with an oxidizing agent, a bissiloxylation reagent, an alkali, a ligand, and a solvent, reacted, and after completion of the reaction, the reaction is quenched and separated to obtain the product; The bissiloxylation reagent is OsO 4 , K 2 OsO 4 , OsO 4 Hydrate and K 2 OsO 4 hydrates; The oxidizing agent is K 3 [Fe(CN) 6 ] or NMO, and The alkali may be potassium carbonate, sodium carbonate, cesium carbonate, potassium hydrogen carbonate, sodium hydrogen carbonate, NaOH, KOH, LiOH, NH 4 OH, t-BuONa, t-BuOK, t-BuOLi, cesium carbonate, triethylamine, diisopropylethylamine, DBU, pyridine and 4-dimethylaminopyridine; The ligand is (DHQ) 2 PHAL, (DHQD) 2 The method for producing an L-erythro-biopterin compound according to claim 14, characterized in that the compound is selected from one or more of PHAL, DHQ-IND and DHQD-IND.

16. When the olefin in the compound represented by formula (II) has a cis structure and the structural formula is a compound represented by formula (IIa), the compound represented by formula (IIa) is produced from a compound represented by formula (V) by catalytic hydrogenation; 【Chemistry 23】 When the olefin in the compound represented by formula (II) has a trans structure and the structural formula is a compound represented by formula (IIb), the compound represented by formula (IIb) is produced from a compound represented by formula (VI) by a coupling reaction; 【Chemistry 24】 The method for producing an L-erythro-biopterin compound according to claim 7, wherein M is H or a leaving group.

17. The catalytic hydrogenation reaction process includes the following steps: The compound represented by formula (V), a catalyst, and a solvent are mixed and reacted in a hydrogen gas atmosphere. After the reaction is completed, the mixture is filtered and concentrated to obtain the compound represented by formula (IIa); The catalyst is selected from one or more of Lindlar's catalyst and palladium on carbon, Raney nickel, platinum black, platinum oxide; The method for producing L-erythro-biopterin compounds according to claim 16, characterized in that the solvent is selected from one or more of tetrahydrofuran and 2-methyltetrahydrofuran, ether, methyl tert-butyl ether, cyclopentyl methyl ether, methanol, ethanol, isopropanol, acetonitrile, and toluene.

18. The coupling reaction process includes the following steps: The compound represented by formula (VI) is mixed with a trans-1-propenylboronic acid reagent, a catalyst, a solvent, and a ligand, and after completion of the reaction, the mixture is separated to obtain the compound represented by formula (IIb); The trans-1-propenylboronic acid reagent is selected from 4,4,5,5-tetramethyl-2-(2-methyl-1-propenyl)-1,3,2-dioxaborolane, trans-1-propenylboronic acid, or trans-1-allyl-fluoroborate; The catalysts are 5% Pd / C and 10% Pd / C, Pd(OAc) 2 , PdCl 2 (PPh 3 ) 2 , Pd(PPh 3 ) 4 , PdCl 2 (dppf), PdCl 2 (MeCN) 2 , Pd 2 (dba) 3 selected from one or more of: The solvent is selected from one or more of methanol, ethanol, isopropanol, butanol, water, tetrahydrofuran, 2-methyltetrahydrofuran, 1.4-dioxane, DME, DMF, DMSO, NMP, acetonitrile, dichloromethane, 1,2-dichloroethane, methyl acetate, ethyl acetate, isopropyl acetate, butyl acetate, ether, methyl tert-butyl ether, toluene, dimethylbenzene, acetone, methyl ethyl ketone, and methylcyclopentane; The ligand is PPh 3 17. The method for producing an L-erythro-biopterin compound according to claim 16, characterized in that the ligand is selected from one or more of the following: BINAP, dppf, Xantphos, Xphos monophosphine and diphosphine ligands.

19. The method for producing an L-erythro-biopterin compound according to claim 16, characterized in that the compound represented by formula (V) is obtained from the compound represented by formula (VI) by Sonogashira reaction. 【Chemistry 25】

20. The Sonogashira reaction process includes the following steps: Mixing the compound represented by formula (VI), a catalyst, a ligand, and a solvent; Alkaline and 【Chemistry 26】 and after completion of the reaction, the reaction is quenched and separated to obtain the compound represented by formula (V).

21. The compound represented by the formula (III) can be obtained by reacting with a compound represented by the formula (II). 【Chemical 27】 and / or 【Chemistry 28】 by cyclization with a salt; 【Chemical Formula 29】 E is halogen, C 1-4 Alkoxy group, C 1-4 Alkylthio group or -NH 2 The method for producing an L-erythrobiopterin compound according to claim 7, characterized in that

22. The method for producing an L-erythro-biopterin compound according to claim 7, characterized in that, when the olefin in the compound represented by formula (III) has a cis structure and the structural formula is a compound represented by formula (IIIa), the compound represented by formula (IIIa) is produced from the compound represented by formula (VIII) by catalytic hydrogenation; 【Chemistry 30】

23. The compound represented by formula (VIII) can be obtained by the following steps: The compound represented by formula (VI) can be reacted with the compound represented by formula (V) by Sonogashira reaction; The compound represented by formula (V) is subjected to a cyclization reaction to obtain a compound represented by formula (VIII); 【Chemistry 31】 The method for producing an L-erythro-biopterin compound according to claim 22, wherein M is H or a leaving group.